CanhamoMAN

pode ter bons, mas 1 laranja podre estraga as outras.... olha que a cesta já esta podre.

07 de Fevereiro de 2014 França comercializa teste para maconha em lojas de cigarros Ouvir (03:54) Adicionar à minha playlist Baixar Embed Fonte:http://www.portugues.rfi.fr/geral/20140207-franca-comercializa-teste-para-maconha-em-lojas-de-cigarros Os testes para maconha serão vendidos em lojas de cigarros em toda a França. autoplus.fr Silvano Mendes Uma empresa francesa lançou um teste para medir o teor de maconha no organismo humano. Batizado de “Cannabis Veredict”, o sistema dá o resultado em apenas cinco minutos e pode ser comprado em qualquer tabacaria do país. O dispositivo, que garante 99% de precisão, é destinado principalmente aos chamados “fumantes esporádicos” da erva. Ao contrário dos testes utilizados atualmente pela polícia francesa, que analisam a saliva do usuário, o “Cannabis Veredict” se baseia em uma amostra de urina para medir o teor de THC (tetrahidrocanabinol) no organismo. A substância produzida pela maconha é a principal responsável pelos efeitos euforizantes da erva. O novo sistema, comercializado pela empresa Elicole, será vendido nas lojas de cigarros francesas. Uma primeira fase de testes está sendo realizada nesse momento e um lote de 100 mil doses já foi distribuído em 3 mil pontos de venda do país. Acidentes de trânsito O objetivo do "Cannabis Veredict" não é saber se um motorista está em condições de dirigir após consumir a droga, e sim se, em caso de controle, ele terá um resultado positivo. Dessa forma, “o teste não serve para os fumantes regulares, pois as pessoas que consomem maconha diariamente sabem que terão um resultado positivo permanente. Ele é mais interessante para os consumidores esporádicos de maconha”, explica Marc Elie, presidente da Elicole. “Esses usuários podem fumar um baseado no fim de semana e, mesmo se não estão mais sob o efeito da droga na segunda-feira, ainda terão resíduos no organismo. E aqui na França, em caso de acidente no trabalho ou no trânsito, um simples resíduo de droga no organismo pode justificar a condenação de um motorista ou de um trabalhador”. A lei francesa prevê multa de 4500 € (quase R$ 15.000), perda de seis pontos na carteira e até dois anos de prisão para quem for supreendido dirigindo sob o efeito de drogas. Atualmente, 13,4% dos acidentes mortais nas estradas franceses foram provocados por pessoas que apresentaram resultado positivo no teste da maconha. Outro público visado pelo empresário são os pais de adolescentes, que poderão testar o teor de maconha em seus próprios filhos. Para ele, esse pode ser um ótimo método de prevenção dentro de casa.

Sano já tava na pauta qnd virou noticia... acho esses caras uns lixo...tem q molhar a mão de muita gente para as coisas andarem.

O mundo está atento à “próxima grande indústria americana” http://www.publico.pt/mundo/noticia/o-mundo-esta-atento-a-proxima-grande-industria-americana-1622918 Por Alexandre Martins e Amílcar Correia 09/02/2014 - 10:23 A legalização da venda e do consumo da cannabis no Colorado e em Washington abriu as portas a um novo mercado, que pode facturar centenas de milhões de euros só este ano. O Colorado legalizou a venda de cannabis em Janeiro AFP É raro que uma proposta de emprego seja notícia e ainda mais raro que abra os noticiários e encontre espaço entre as piadas dos mais importantes talk shows norte-americanos. Mas neste caso era difícil resistir à tentação. O jornal Denver Post, o maior do estado do Colorado, procurava um editor para um site inteiramente dedicado a notícias sobre cannabis. É raro que uma proposta de emprego seja notícia e ainda mais raro que abra noticiários e encontre um espaço entre as piadas dos mais importantes talk-shows norte-americanos. Mas neste caso era difícil resistir à tentação. O jornal The Denver Post, o maior do estado do Colorado, procurava um editor para um site A proposta foi afixada numa das paredes da redacção, em Novembro, e tornou-se rapidamente num dos assuntos mais quentes no Twitter, depois de um dos jornalistas da casa ter partilhado uma fotografia do texto: “<i>The Denver Post</i> está a contratar um editor para coordenar a criação e a manutenção de um site sobre o uso de marijuana para fins recreativos.” Os eleitores do Colorado tinham acabado de aprovar em referendo a legalização do consumo e da venda de cannabis para fins recreativos a maiores de 21 anos de idade, tornado-se no segundo estado norte-americano a fazê-lo, juntamente com Washington. Com uma lei um pouco mais ambiciosa do que os seus compariotas da costa Oeste, os habitantes do Colorado vivem agora – desde o dia 1 de Janeiro – no território mais permissivo do mundo em relação ao consumo e venda de cannabis. Apesar das candidaturas expontâneas ao cargo de “editor de erva” de The Denver Post que explodiram nas redes sociais, a oferta era interna: o escolhido foi Ricardo Baca, um jornalista experiente que passara os últimos 15 anos a escrever sobre música. Ao PÚBLICO, Ricardo Baca explicou o que representa o facto de um jornal de grande circulação (mais de 415.000 exemplares por dia) ter sentido a necessidade de acompanhar diariamente a informação sobre o consumo e venda de cannabis. “A decisão de The Denver Post de criar um site e a nomeação de um editor é uma indicação clara do potencial que existe para a criação de um novo mercado. Muitas pessoas consideram que a venda legal de cannabis será a próxima grande indústria americana.” É tudo muito recente, mas as estimativas apontam para centenas de milhões de dólares só no primeiro ano após a legalização. “Prevê-se que, só no Colorado, o montante dos impostos recolhidos devido a esta actividade ultrapasse os 40 milhões de dólares em 2014, que serão investidos na construção de escolas, por exemplo”, diz o editor do The Denver Post. Foi essa a troca proposta pelos defensores da legalização aos eleitores do Colorado. Quem tem mais de 21 anos de idade pode consumir livremente, desde que não seja em locais públicos; e quem quiser aproveitar a criação de um novo mercado, pode vender em espaços comerciais regulamentados. O dinheiro dos impostos vai para as escolas e o tempo gasto pela polícia a perseguir os consumidores é dedicado à criminalidade mais violenta. À margem da lei federal O problema é que a lei do estado do Colorado está à margem da lei federal. Como a cannabis figura na lista de substâncias ilegais do Departamento de Justiça norte-americano, os bancos do Colorado não arriscam fazer negócios com os exploradores da “próxima grande indústria americana”, como lhe chama o jornalista Ricardo Baca. O procurador-geral dos EUA, Eric Holder, anunciou há duas semanas que esse problema seria resolvido “em breve”, mas nem disse quando, nem explicou como. “Esse é um dos principais problemas”, diz Baca. “E ninguém sabe se será resolvido daqui a duas semanas, ou ainda em 2014.” Apesar de todos os nós que ainda estão por desatar, as sondagens nos EUA e as políticas seguidas em vários países da América Latina sinalizam uma tendência favorável à legalização. Pela primeira vez na História, a maioria dos norte-americanos defende a legalização do consumo de cannabis para fins recreativos, de acordo com sondagens de institutos como o Pew Research Center e a Gallup. E o que se passa na Europa, enquanto na América se discute a legalização? Vamos por partes. Recentemente, o Uruguai e os estados norte-americanos do Colorado e de Washington legalizaram a venda de cannabis. E o Presidente Barack Obama, um fumador confesso de marijuana nos tempos de escola, fez as declarações mais simbólicas a propósito deste tema: legalizar a “‘cannabis’ é uma questão de justiça social”; “fumar marijuana não é mais perigoso do que o álcool”. Há duas semanas, no Fórum Económico Mundial, Kofi Annan dizia: “As drogas destruíram muita gente, mas as políticas erradas dos governos destruíram muitas mais”. O ex-secretário-geral das Nações Unidas juntou-se a um número cada vez mais crescente de pessoas que admite, sem hesitação, que é necessário acabar com o encarceramento de consumidores e que a legalização adoptada naqueles dois estados norte-americanos é “apenas um passo”. O caso português Quando Obama, Annan, Fernando Henrique Cardoso (que preside à Comissão Global de Políticas sobre Drogas) ou Jorge Sampaio clamam por outras políticas sobre as drogas, não será porque algo está definitivamente a mudar? Será possível, e desejável, fazê-lo também em Portugal e no resto da Europa? Será a legalização uma tendência internacional? Descriminalizar o consumo de droga em Portugal, em 2001, durante um Governo de António Guterres e com Jorge Sampaio em Belém, foi uma estratégia adoptada para resolver o que aparentemente não era resolúvel: como lidar com uma população prisional repleta de consumidores ou de pequenos consumidores-traficantes e com elevadas taxas de HIV e hepatite entre um conjunto substancial de pessoas que se injectavam por via endovenosa. Descriminalizar o consumo, na sequência de um plano estratégico que substitui o discurso do senso comum por um discurso de base científica, retirou ao toxicodependente o estatuto de criminoso e substitui-o pelo do doente. É esta "visão humanista" do consumo de drogas, como por vezes se lhe chama, que tem justificado elogios à política portuguesa e prémios e reconhecimento a alguns do seus protagonistas. "Portugal foi pioneiro na descriminalização do consumo de droga e constitui um laboratório onde inúmeros países europeus têm vindo perceber os efeitos práticos da medida", disse ao PÚBLICO João Goulão. Na sua qualidade de director-geral do Serviço de Intervenção nos Comportamentos Aditivos e nas Dependências (SICAD) e presidente do Conselho da Administração do Observatório Europeu das Drogas e da Toxicodependência (OEDT), Goulão acrescenta que a "atitude europeia é a de perceber se a legalização do consumo de cannabis no Uruguai e em dois estados dos EUA tem efeitos positivos". Na mesma linha prudente, Goulão observa que, na actual conjuntura, a "Europa não estará muito disponível" para adoptar políticas de legalização e que estará mais empenhada na tal "visão humanista", numa "abordagem inspirada pela estratégia portuguesa". Há, no entanto, um factor recente que obriga a encarar o consumo de cannabis com outra atenção. Em Portugal, os últimos dados referem que a cannabis ultrapassou a heroína entre os casos de consumidores que procuram tratamento, algo que não é inédito em outros países europeus, onde o seu consumo está mais generalizado. O relatório anual de 2012 “A Situação do País em Matéria de Drogas e Toxicodependência”, apresentado pelo SICAD em Dezembro, confirma a heroína como responsável por 84 por cento dos casos tratados em ambulatório, mas ressalva que, nesse ano, o número de novos consumidores a iniciar tratamento por cannabis foi de 38 por cento, ao passo que a heroína foi responsável por 34 por cento. A sanção administrativa aplicada aos consumidores de droga em Portugal, que implica uma passagem pelas comissões de dissuasão, contribui, acreditam os responsáveis do SICAD, para que os consumidores "reflictam sobre os seus próprios consumos". Eles, os consumidores, "acabam por assumir que a cannabis não é tão inócua quanto se pensa", conclui Goulão, uma vez que aquela substância é hoje "psicoactivamente mais poderosa" do que alguma vez foi, fruto das possibilidades de manipulação de que pode ser objecto o seu princípio activo (THC). A legalização da cannabis, agora que a droga foi paulatinamente deixando de estar na agenda política do país, é uma batalha avulsa e irregular por parte de uma ou outra juventude partidária e por insistência do Bloco de Esquerda. O partido de João Semedo e Catarina Martins defende a legalização do consumo e não só: a possibilidade do seu cultivo para consumo pessoal e a criação de "clubes sociais" (associações que se dediquem ao estudo, investigação, debate, mas também ao cultivo devidamente autorizado). Tendência internacional? Não obstante, existem iniciativas de cidadania europeia com esse objectivo e que procuram reunir um milhão de assinaturas para pedir uma alteração legal na União Europeia. Jakob Huber, director do Contact Netz, uma organização que se dedica à prevenção e redução de riscos e que criou a primeira sala de injecção assistida, na Suíça, é claro: "A proibição falhou" e é "necessário adoptar a regulação das substâncias e descriminalização dos consumidores". O que Huber defende é a regulação e não a legalização. "Falo de regulação legal, à semelhança do álcool. Mas podemos regular melhor, por exemplo, proibir, nos dois casos, o marketing e a publicidade a estes produtos.” Para todos os efeitos, como nota Danilo Ballotta, especialista em políticas de droga do OEDT, "nunca na história das políticas das drogas, desde o primeiro acordo internacional, em Xangai, em 1902, posições tão distintas do quadro legal previamente em vigor tinham resultado em normas para legalizar uma droga, incluindo a produção e venda”. Danilo relaciona a recente afirmação de Barack Obama com o memorando do vice-procurador-geral norte-americano James Cole, enviado a todos os procuradores e forças policiais federais dos EUA a 29 de Agosto passado, no qual assume uma vontade política de permitir a experiência nos dois estados, apesar da oposição da lei federal. Doze dias depois, em resposta ao senador Patrick Leahy, presidente da Comissão de Assuntos Judiciais do Senado, James Cole explicou que era preferível que o dinheiro da droga fosse canalizado para a cobrança fiscal em vez de destinado ao crime organizado, com o Estado a regular o cultivo e a venda da substância. Um segundo factor pode resultar desta mudança de atitude: a população vai tomar consciência de que as autoridades policiais vão ter "mais tempo para combater a criminalidade", e não os consumidores, e que o dinheiro que resulte da legalização pode ser empenhado na comunidade em programas de prevenção e tratamento. Como sublinha Danilo Ballotta, estas políticas nos EUA surgem na sequência das estruturas criadas para a venda medicinal de "cannabis", que é legal em cerca de 30 estados do país. E qual será a influência que estas medidas poderão exercer a uma escala global? E qual será a resposta dos estados – e não são poucos – que têm orientações totalmente opostas? A resposta poderá ser conhecida em 2016, na UNGASS, a assembleia que a ONU irá dedicar às políticas de drogas. E se os defensores da legalização conseguirem reunir as assinaturas suficientes para forçarem a realização de referendos na Califórnia, no Oregon, no Arizona ou no Alaska, no final deste ano, os seus resultados também poderão apontar o caminho.

já disse que temos que trazer politicos da Suecia(já trouxemos medicos de Cuba mesmo), e juizes dos EUA.... por que aqui esses são uns lixo... ninguem poe fé neles... eles não trabalham com empenho, não tem metas mesmo... aumentar salario baseado em metas eles fogem....

09/02/2014 07h25- Atualizado em 09/02/2014 07h25 De black bloc a Marcha da Maconha: atos viram tema de marchinha no Rio Dos dez finalistas de concurso da Fundição Progresso, 4 falam de protestos. Vandalismo, Bope e Batalhão de Choque também são citados; ouça músicas. http://g1.globo.com/rio-de-janeiro/carnaval/2014/noticia/2014/02/de-black-bloc-marcha-da-maconha-atos-viram-tema-de-marchinha-no-rio.html Cristiane CardosoDo G1 Rio Uma das mais tradicionais disputas musicais do Brasil chegou a sua fase final com um assunto recorrente. Os protestos que se tornaram frequentes em todo o país desde junho vai subir ao palco do 9º Concurso Nacional de Marchinhas Carnavalescas. A temática vai de questões cariocas, como o sumiço de vigas da Perimetral, a pontos mais abrangentes do Estado e de todo o território nacional, como a Marcha da Maconha e a tática de ação em protestos conhecida como black block (ouça trechos das canções no vídeo ao lado). A decisão acontecerá no domingo (16) na Fundição Progresso, na Lapa, região central da cidade, onde um baile vai celebrar as dez canções escolhidas. Todas elas serão gravadas em um CD, mas apenas uma será a grande vencedora do ano. Senhor prefeito Não é intriga Aonde foi Que enfiaram àquela viga!" "Cadê a Viga?" Cassio e Rita Tucunduva Dentre as finalistas, três falam diretamente de assuntos relacionados às manifestações da cidade. Outra, ironiza justamente esta monotemática. Em "Eu Quero é Ficar Off", os autores abrem mão de falar do pré-sal, dos vinte centavos e do vandalismo. "Eu não quero reclamar nada, neca, nadica de nada", diz a canção. Em meio aos confetes e serpentina, mas ainda assim engajado, o músico Oswaldo G Pereira, que revelou ter uma simpatia ao movimento black block, canta a paixão carnavalesca por uma integrante do grupo. "O nosso amor é feito uma cidade / De prosperidade e paz", canta ele. Outras seis músicas fazem parte da disputa, com títulos como "Lenço de Cetim", "Colorindo a Praça" e "Baba do Quiabo". Em marchinha, Oswaldo G Pereira se declarou à tática black bloc (Foto: Reprodução/G1) Serviço: Finalíssima do Concurso Nacional de Marchinhas Com Cordão do Boitatá e Banda Fundição Data:16 de fevereiro, domingo Local: Fundição Progresso (Rua dos Arcos, 24 – Lapa - Rio de Janeiro) Classificação etária: livre. Preços: R$ 20,00 (inteira)

Saiu o Britto entrou Joaquim Barbosa e não anda nada... BRASIL!!!... isso que esperamos da Justiça.... ela parada para coisas importantes ou até DESandando ... governo CABIDE DE EMPREGO, SEM METAS NÃO VAI! to falando que vou pegar varios no dia da mentira aqui novamente...

é nois!!!!

Hemp, Inc. Applauds President Obama for Legalizing Industrial Hemp GlobeNewswire Monday, February 10th 2014 http://www.virtual-strategy.com/2014/02/10/hemp-inc-applauds-president-obama-legalizing-industrial-hemp LAS VEGAS, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Hemp, Inc. (OTC:HEMP) applauds President Obama for signing the 2014 Agricultural Act into law which contained a provision making it legal, under Federal law, for universities and state agricultural departments to grow and research the industrial properties of hemp without penalty, in states where the once controversial crop is legal. This will open enormous new economic opportunities for Hemp, Inc. as the only industrial hemp publicly traded company. Those states, currently, are California, Colorado, Kentucky, Maine, Montana, North Dakota, Oregon, Vermont, Washington and West Virginia. Prominent industry staples such as Hemp, Inc. (OTC:HEMP) are positioned to profit considerably from what could be the first step toward creating a multi-billion dollar hemp industry. The 2014 Agricultural Act, known as the Farm Bill, was celebrated in the industry because it represents the first time in decades that industrial hemp was defined by federal law since the non-intoxicating plant was erroneously banned under the 1970 Controlled Substances Act. All forms of cannabis are federally prohibited under the Controlled Substances Act because marijuana has psychoactive properties. Even though hemp is in the same genus as marijuana, it does not contain any THC to "get high". What does this mean for the industrial hemp industry? The classification of industrial hemp is not permanent. "Outlawing hemp because of its association with marijuana was one of the most counterproductive measures in U.S. history. But after decades of ignorance and misinformation, hemp can finally be differentiated from its potent cousin, marijuana allowing more legislation to be passed specific to hemp. Once it's permanently removed from the Controlled Substances Act, hemp will, once again, become a significant driving force in the U.S. economy," opined Bruce Perlowin, CEO of the first public company in the industry, Hemp, Inc. (OTC:HEMP). The Farm Bill's provision on industrial hemp allows states to draft their own administrative rules, which means they have the flexibility to outsource cultivation to local farmers and can begin growing as soon as the local rules are accepted. According to the bill, there is no cap on the amount of hemp that can be grown, or for the size of a research facility. Prior to the bill, annual retail sales in the industrial hemp industry was estimated at over $500 million. "Just think how it will increase now. This is monumental," said Perlowin. "The market opportunities for hemp, especially for Hemp, Inc. are astounding ... expanding into the mainstream. With our 108-acre hemp crop, in the Gansu Province of Northwest China, it's exciting to be offering hemp goods that Hemp, Inc. has produced from seed to sale." Hemp, Inc. teamed up with the Yasheng Group, one of China's largest agricultural producers, last year and has been growing industrial hemp which is in high demand by consumers because the seeds are packed with essential fatty acids and proteins and unlike soy, hemp is not genetically modified. The other components of the crop are fiber, intended for textile use, and chaff for animal bedding and for use in hemp concrete. Hemp, Inc. is currently negotiating for expanded hemp cultivation ventures with Yasheng Group for Spring, 2014. "Our intent for this is to establish processing facilities onsite. Northwest China's environment is perfectly suited for the hemp plant, but it is a challenge getting goods to processing facilities and finally to market, so getting ramped up is key," said Perlowin. With the demand for hemp food in America, Hemp, Inc. stands to gain a sizeable market share. The retail value of its harvest, in seed products alone, "could be well over $2,000,000" according to a previous release where Hemp, Inc. informed shareholders of their crop's progress. The crop also "consists of a Hemp cultivar suitable for textile manufacturing. These hemp fibers will be blended with cotton or other natural fibers and made into soft, durable garments such as T-shirts." With a solid infrastructure to manufacture, Hemp, Inc. has positioned itself as the cutting edge leader at the birth of this new industry or the avant garde of the industrial hemp industry. A value-added part of Hemp, Inc.'s crop is the plant's chaff. The chaff is highly absorbent and obtained by mechanical de-fibering after the seeds are removed and is used for wet process hemp concrete building applications and animal bedding. "We are using the chaff for hemp adobe bricks for the hemp houses we're building on our KinsDomain in Arizona and Florida," said Perlowin. Hemp, Inc. is building hemp houses on 4,500 acres in Arizona and in southern and central Florida. According to Eric Steenstra, President of the advocacy group, Vote Hemp, "This is not just a boon to U.S. farmers, this is a boon to U.S. manufacturing industries as well." As the laws around industrial hemp continue to unfold, industry newcomers and investors are looking for professional guidance and they are turning to Hemp, Inc.'s subsidiary, The Industrial Hemp and Medical Marijuana Consulting Company, Inc. (IHMMCC). Bruce Perlowin, CEO of Hemp, Inc. says, "I know where all the gold is hidden in this industry, every nuance of business niche, what will work and won't work, what has been tried before and what new ideas and concepts for the industry will fly or fail. When I'm not sure of something, or it's in one of the many areas outside my particular expertise then I know who to go to, who is an expert in this area and who more likely than not will immediately know all the answers or where to find them quickly. Our consulting division is extremely diverse and broad." The Industrial Hemp and Medical Marijuana Consulting Company, Inc. pulls industry information from a vast network of specialists that consists of other public industry, public companies' CEOs and networks of experts, bankers, investors, lawyers, other consultants, industry analysts, and non-profits connected to this industry as well as the traditional industry experts in all areas of the various business opportunities the industry presents. Perlowin, and his associates, have an unrivaled wealth of knowledge and experience. This culmination of knowledge and experience has even attracted the attention of banks, which want in on the billions of dollars flowing through the public company sector of this industry. Hemp, Inc. is also producing hemp-based products proven to increase the body's overall health and performance. The company boasts HerbaGenixTM nutraceuticals (www.herbagenix.com); BasicHemp (www.basichemp.com), their hemp protein shakes brand; and, custom-branded MJ Lover for Him and MJ Lover for Her (www.mjlover.com) and Re-Load's hemp nutraceuticals (www.re-load.biz) which are derived from a blend of organic nutrients, herbs, and vitamins including hemp extract, and AFA blue-green algae which is known for its healthful effects. Other products of Hemp, Inc. include hemp gemstone candles (www.supportpatchadams.com) made on the Kins Domain; the Eco-Harmony Loyalty Card (www.ecoharmonycard.com); and, education and media (www.marijuanaincorporated.com). Hemp, Inc.'s diversification also expands into the apparel industry with their hemp and natural fibre clothing (www.cartelblue.com) launching Spring, 2014. Cartel Blue will manufacture hemp jeans and other eco-friendly clothing. The apparel line's physical advantages are its hemp fibers due to its length, strength, durability, elasticity, and ability to withstand high temperatures without degeneration. It also has antimicrobial properties, as hemp is resistant to the growth of Aspergillus Niger ... a fungus and one of the most common species of the genus Aspergillus. It causes a disease called black mold and is ubiquitous in soil, commonly reported from indoor environments. Furthermore, hemp can be grown without or very minimal herbicides and pesticides. In comparing hemp to cotton, a textile used in producing many garments, studies show cotton uses about 50% of the world's toxic crop chemicals and not only is hemp stronger, but it lasts longer, is more absorbent, warmer, breathes better, and is more microbially-resistant. Not to mention, hemp requires only a third as much water as cotton to grow and only a tiny fraction of the fertilizer, pesticide and herbicide that cotton does. Aside from IHMMCC, Hemp, Inc. is poised to have Hemp, Inc. (http://www.hempinc.com) become the 'Amazon' of the hemp world, as they expect continued rapid growth in the industry. Their website is the definitive portal for all other hemp company products. ABOUT HEMP, INC. Hemp, Inc. (OTC:HEMP) focuses on the vast market created by the quickly emerging, and growing, multibillion dollar industrial hemp industry. Hemp, Inc. (OTC:HEMP) is not involved in the cultivation or marketing of medical marijuana. It is the company's belief that legalization of hemp in all 50 states and at the federal level will come to pass. With that in mind, the company is building infrastructure with the potential to gain substantial market share before and after industrial hemp prohibition ends. (Pending any federal licensing or other requirements, that may be enacted after hemp prohibition ends). ABOUT THE INDUSTRIAL HEMP AND MEDICAL MARIJUANA CONSULTING COMPANY, INC. The Industrial Hemp and Medical Marijuana Consulting Company (IHMMCC) is a wholly owned subsidiary of Hemp, Inc. (OTC:HEMP) that pulls industry information from a vast network of specialists that consists of other public industry, public company CEOs, bankers, investors, lawyers, industry analysts, and non-profits connected to the industry. IHMMCC is entrenched in all the multi-faceted opportunities in the medical marijuana and Industrial Hemp industry. (www.HempInc.com) Hemp, Inc.'s TRIPLE BOTTOM LINE Hemp, Inc. (HEMP) seeks to benefit many constituencies, not exploit or endanger any group of them. Thus, the publicly-traded company believes in "upstreaming" of a portion of profit from the marketing of their finished hemp goods back to its originator. By Hemp, Inc. focusing on comprehensive investment results that is, with respect to performance along the interrelated dimensions of people, planet, and profits our triple bottom line approach can be an important tool to support sustainability goals. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Hemp, Inc. to be materially different from the statements made herein. Contact: 855-HempOut email: info@hemp.comhttp://www.hemp.com http://www.herbagenix.com (hemp based supplements division) http://www.basichemp.com (hemp protein with enhanced nutritionals) http://www.mjlover.com (MJ Lover for Him; MJ Lover for Her) http://www.re-load.biz (hemp-based nutraceuticals) http://www.ecoharmonycard.com (loyalty card sustainable fundraiser for non-profits) http://www.supportpatchadams.com (hemp gemstone candles and fundraiser for patch adams) http://www.hempinc.tv (media and entertainment division) http://www.marijuanaincorporated.com http://www.cartelblue.com (eco-friendly clothing) president-obama-legalizing-industrial-hemp?page=0,2#OisQGO1w4ThcS51b.99Read more: http://www.virtual-strategy.com/2014/02/10/hemp-inc-applauds-president-obama-legalizing-industrial-hemp#ixzz2sv6EDqnE

Académico quirguiz: a legalização da marijuana mantém os governos no poder Tradução publicada em 7 Fevereiro, 2014 10:49 GMT · Veja o post original [en] http://pt.globalvoicesonline.org/2014/02/07/academico-quirguiz-a-legalizacao-da-marijuana-mantem-os-governos-no-poder/ Com os recentes comentários sobre a marijuana [en] do Presidente dos EUA, Barack Obama, reacende-se o debate sobre a sua liberalização no mundo, inclusive no Quirguistão, onde um académico quirguiz propõe uma explicação não usual para a descriminalização da marijuana em vários países. Num artigo do blogue kloop.kg, Rustam Tukhvatshin afirma [ru] que a legalização ajuda os governos a controlar os movimentos de protesto: …La adicción de la gente a la [marihuana] es muy conveniente a los políticos porque los adictos individuales nunca los criticarán. Tales personas verán cualquier decisión política, hecha por los políticos a través de una pantalla de humo de la marihuana, con alegría y complacencia. Lo mas frecuente es que los individuos [adictos a la droga] pertenecen a los estratos mas descontentos y la legalización de la marihuana representa a estos estratos [sin importancia]. Lamentablemente las personas que usan marihuana están a solo un paso de experimentar con drogas mas duras tales como la heroína y el LSD. Esto permite entonces a las autoridades incluir a estas personas en el registro y tomar medidas contra ellos, mientras que la sociedad en general no defenderá jamás a los drogadictos. En mi opinión estas son las principales razones para despenalizar la marihuana… …A dependência das pessoas [da marijuana] é muito conveniente para os políticos porque estes nunca serão criticados pelos indivíduos viciados. Essas pessoas verão qualquer decisão política tomada pelos políticos através de uma nuvem de fumo de marijuana, de forma alegre e complacente. Frequentemente, estes indivíduos [dependentes da droga] pertencem a estratos sociais mais descontentes e a legalização da marijuana representa estes estratos [sem importância]. Infelizmente, as pessoas que consomem marijuana estão apenas a um passo de experimentar drogas mais pesadas, tais como Heroína e LSD. O que permite então às autoridades fazer um registo destas pessoas e tomar medidas contra elas, uma vez que a sociedade em geral nunca irá defender os toxicodependentes. Na minha opinião, estas são as principais razões para despenalizar a marijuana…

Health benefits of Hemp seed oil Last Updated: Thursday, January 30, 2014, 16:29 Pic Courtesy: - http://zeenews.india.com/news/health/healthy-eating/health-benefits-of-hemp-seed-oil_26432.html Zee Media Bureau Washington: Hemp seed oil, pressed from the seeds of the Cannabis sativa plant, is making a comeback, not just as a source of fibre for textiles, but also as a crop packed with oils that have potential health benefits. Long been stigmatized because of its "high"-inducing cousins, hemp - derived from low- hallucinogenic varieties of cannabis - have high levels of vitamins A, C and E and beta carotene, and is rich in protein, carbohydrates, minerals and fibre. Maria Angeles Fernandez-Arche and colleagues note that for millennia, people around the world cultivated cannabis for textiles, medicine and food. With increasing interest in plant oils as a source of healthful compounds, Fernandez-Arche's team wanted to investigate hemp seed oil's potential. They did a detailed analysis of a portion of hemp seed oil. They found it has a variety of interesting substances, such as sterols, aliphatic alcohols and linolenic acids, that research suggests promote good health. For example, it contains linolenic acid, which is an omega-3 fatty acid that some studies suggest helps prevent coronary heart disease. The research is published in ACS' Journal of Agricultural and Food Chemistry. Other known health benefits of Hemp seeds are: Hemp seed oil, which contains Omega 3, 6, and 9, is a great alternative to fish oil. The essential fatty acids help restore health and immune function. It is said to help with eczema, asthma, heart disease, high blood pressure. It is not only used to nourish dry skin but blotches and lesions as well. It can detoxify the skin and even out skin tone. It is also a natural sunblock. It has unequalled anti-inflammatory properties Helps relieve premenstrual stress (With Agency Inputs) Health.india.com First Published: Thursday, January 30, 2014, 15:49

PhytoSPHERE Systems, a CannaVest Corp. Subsidiary, Significantly Increased Hemp Oil Production for 2014 PhytoSPHERE Systems Increases Production by Over 1500% From 2013 February 05, 2014 09:00 | Source:CannaVest Corp. http://globenewswire.com/news-release/2014/02/05/607639/10067058/en/PhytoSPHERE-Systems-a-CannaVest-Corp-Subsidiary-Significantly-Increased-Hemp-Oil-Production-for-2014.html LAS VEGAS, Feb. 5, 2014 (GLOBE NEWSWIRE) -- CannaVest Corp. (OTC:CANV), the world's leading cannabis-based investment company spearheading the development of cannabidiol (CBD)-rich hemp oils and other industry-related products and services, is pleased to announce that its subsidiary, PhytoSPHERE Systems, has increased its industrial hemp oil production over 1500% for the 2014 season. The company has also increased its production capabilities to concentrate these hemp oils into high value CBD-rich hemp oils, from the rate of several kilograms per batch production cycle in 2013 to over twenty tons per batch production cycle for 2014. "With this drastic increase in our production and our refining capabilities, we will continue to be able to significantly decrease our production costs and increase our operating margins," stated Michael Mona Jr., President and Chairman of the Board for CannaVest Corp. "The market interest in CBD-rich hemp oils has significantly increased over the past year, due in large part to the many remarkable documentaries and publicity surrounding the positive benefits of cannabis, specifically natural cannabidiol. We are at the forefront of hemp oil production today, and as the legal markets continue to expand we are one of the few companies actually able to capture and benefit from that increased demand." Over the past year, the Company released its flagship CBD-rich hemp oil product, Real Scientific Hemp Oil™ (RSHO™), and developed a multi-award winning prototype CBD extract called CBD Simple, which won the 2013 High Times Cannabis Cup competition in Amsterdam for Highest CBD Concentrate. This international judging event featured entries by the most prominent growers, breeders and producers of cannabis and cannabis products worldwide. CBD Simple also won the 2013 Seattle High Times Cannabis Cup and 2013 Michigan Medical Marijuana Conference "Green Cup" contests for Highest CBD Concentrate. In addition, the Company launched a line of popular everyday CBD-rich hemp oil supplements, Cibdex™, now available in drops or capsules—and the world's first natural hair and body care line with CBD-rich hemp oil, Cibaderm™. These products can be purchased at the following sites: HempMedsPX™ http://www.HempMedsPX.com 866.273.8502 Real Scientific Hemp Oil™ http://RealScientificHempOil.com 866.273.8502 Cibdex™ http://www.cibdex.com 866.273.8502 Cibaderm™ http://www.cibaderm.com 866.273.8502 "We are very pleased with the performance of our products in these competitions and look forward to a strong performance in 2014," continued Mona Jr. About CannaVest Corp. CannaVest Corp. is in the business of investing and developing hemp-based businesses. CannaVest Corp. also develops, produces, markets and sells end-consumer products to the nutraceutical industry containing the hemp plant extract, cannabidiol (CBD). Additionally, the company resells—to third parties—raw product acquired by CannaVest Corp. pursuant to the company's supply international relationships. CannaVest Corp. seeks to take advantage of an emerging worldwide trend to re-energize the production of industrial hemp and to foster its many uses for consumers. Cannabinoids (cannabidiol/CBD) are natural constituents of the hemp plant, and CBD is derived from hemp stalk and seed. Additional information is available from OTCMarkets.com or by visiting CannaVest.com. About PhytoSPHERE Systems PhytoSPHERE Systems is a global phytocannabinoid biotechnology company based in San Diego, California with an exclusive license for use by CannaVest Corp. (OTC:CANV). The company utilizes advanced cultivation methods and state-of-the-art processing technology leading to development of pharmaceutical, nutraceutical and food products. PhytoSPHERE Systems, the manufacturer of the CBD-rich hemp oil used in Real Scientific Hemp Oil (RSHO), has developed special cultivars (similar to "strains") that produce hemp that is especially rich in CBD, making it possible for PhytoSPHERE to offer all-natural products with high concentrations of hemp-based CBD. For more information, visit: PhytoSPHERESystems.com About HempMedsPX HempMedsPX offers mainstream marketing, sales, customer service, and logistics for the cannabis industry. HempMedsPX is a corporate portfolio company of Medical Marijuana, Inc. (OTC Pink:MJNA) and the exclusive master distributor and contracted marketing company for CannaVest Corp. (OTC:CANV) and Medical Marijuana Inc. In addition to handling sales and distribution, HempMedsPX is the communication hub for the Medical Marijuana Inc. portfolio of companies. LEGAL DISCLOSURE CannaVest Corp. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell and distribute hemp based products and is involved with federally legal distribution of medical marijuana-based products within certain international markets. We use the following names for informational purposes only, all of which refer to the legal industrial hemp plant: cannabis, canipa, kanipa, kanna, canna, kanabis, marijuana, medical marijuana, hemp, and industrial hemp. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein. FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Corporate Contact: CannaVest Corp. 2688 South Rainbow Avenue, Suite B Las Vegas, NV 89146 Phone: 866-290-2157 www.cannavest.com

February 6, 2014, 4:40 a.m. ET VaporBrands International, Inc. to Market Hemp Oil in Electronic Cigarettes http://online.wsj.com/article/PR-CO-20140206-905376.html VaporBrands International, Inc. to Market Hemp Oil in Electronic Cigarettes LOS ANGELES, CA--(Marketwired - Feb 6, 2014) - VaporBrands International, Inc. (OTC Pink: VAPR) (the "Company" or "VaporBrands")and HEMP, Inc. (OTC Pink: HEMP) announced today that VaporBrands will market Hemp Oil produced by Marijuana, Inc. a wholly owned subsidiary of Hemp, Inc., in electronic cigarettes supplied by VaporBrands for medicinal purposes and recreational use, where legal. The two companies have formulated a strategic plan for the development of and use of Hemp Oil in specialized adaptations of VaporBrands' electronic vaporization products for use in the field of marijuana-based medicine. VaporBrands and Hemp signed a Letter of Intent on January 28, 2014 with Marijuana, Inc., a wholly owned subsidiary of Hemp, Inc., a leading provider of products and services for the industrial hemp and medical marijuana industries. Under the terms of the Joint Venture's strategic plan specially designed vaporizing products, including electronic cigarettes will be supplied by VaporBrands' to the Joint Venture and marketed through Medical Marijuana dispensaries and eventually retail marijuana superstores in Colorado and Washington when operational. VaporBrands and Marijuana, Inc. have agreed to research, develop and distribute vaporizer products specifically for the use of Hemp Oil in natural medicine. Marijuana, Inc. has also agreed to assist VaporBrands in expanding the retail distribution of its current and future electronic nicotine based cigarette products. Based on the current and projected positive market conditions for legal marijuana (medical and recreational), the Company anticipates significant demand for VaporBrands and Marijuana, Inc. co-developed vaporizing products among a wide cross-section of users that are seeking the safest and most effective way to consume marijuana. About Marijuana, Inc. (OTC Pink: HEMP) Marijuana, Inc. is a wholly owned subsidiary of Hemp, Inc. which focuses on supplying services, products, and information related to the medical marijuana industry or to those who have an affinity for the medical marijuana industry. The company website will offer news, issues, entertainment, and education on medical cannabis issues; developing proprietary software for transaction processing, MIS, loyalty program, and social network management; and producing video content that deals with current events as they relate to the industry and is available in high definition over the Internet. Hemp, Inc.'s products include hemp nutraceutical products designed to improve concentration and joint flexibility, increase awareness and energy, and improve overall wellness, as well as to supply hemp and blue-green algae protein; and skin care products for men and women. Hemp, Inc. was founded in 2008 and is based in Las Vegas, Nevada. About VaporBrands International Inc. (VAPR) Vapor Brands International, Inc. is a marketing and development partner for manufacturers of electronic cigarettes. Electronic cigarettes represent the future of smoking; they produce no smoke, tar, ash or offensive odor while containing about the same amount of nicotine as traditional tobacco cigarettes. Unlike traditional tobacco cigarettes, electronic cigarettes can be used in many public places currently restricted from smoking. VAPR intends to focus on creating opportunities for culturally relevant brands seeking to acquire significant market share in the rapidly growing "vaping" sector of the global market. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Hemp, Inc. to be materially different from the statements made herein. Wendy Haviland VaporBrands International, Inc. whaviland@vaporbrands.com The Wall Street Journal news department was not involved in the creation of this content.

Hemp Oil to Replace Olive Oil in the Kitchen? York Scientists Investigate http://www.minsterfm.com/news/local/1202702/hemp-oil-to-replace-olive-oil-in-the-kitchen-york-scientists-investigate/ 9:19am 10th February 2014 Scientists at the University of York today report the development of hemp plants with a dramatically increased content of oleic acid. The new oil profile results in an attractive cooking oil that is similar to olive oil in terms of fatty acid content having a much longer shelf life as well as greater heat tolerance and potentially more industrial applications. Researchers in the Centre for Novel Agricultural Products (CNAP) in the Department of Biology at York say that high oleic acid varieties are a major step towards developing hemp as a commercially attractive break crop for cereal farmers. The research is published in Plant Biotechnology Journal. Using fast-track molecular plant breeding, the scientists selected hemp plants lacking the active form of an enzyme involved in making polyunsaturated fatty acids. These plants made less poly-unsaturated fatty acids and instead accumulated higher levels of the mono-unsaturated oleic acid. The research team used conventional plant breeding techniques to develop the plants into a "High Oleic Hemp" line and higher oleic acid content was demonstrated in a Yorkshire field trial. Oil from the new line was almost 80 per cent oleic acid, compared with typical values of less than 10 per cent in the standard hemp line. This high mono-unsaturated/low poly-unsaturated fatty acid profile increases the oil's thermal stability and oil from the new line was shown to have around five times the stability of standard hemp oil. This not only makes the oil more valuable as a cooking oil but also increases its usefulness for high temperature industrial processes. As oilseed rape faces declining yields and increasing attacks from pest and disease, UK farming needs another break crop to ensure the sustainability of its agriculture and maintain cereal yields. An improved hemp crop, yielding high quality oil would provide an excellent alternative. Hemp is a low-input crop and is also dual-purpose, with the straw being used as a fibre (for bedding, composites and textiles), for biomass and as a source of high value waxes and secondary metabolites. Professor Ian Graham, from CNAP, said: "The new line represents a major improvement in hemp as an oil crop. Similar developments in soybean and oilseed rape have opened up new markets for these crops, due to the perceived healthiness and increased stability of their oil." In 2014 field trials of the new High Oleic Hemp are being rolled out across Europe in order to establish agronomic performance and yield under a range of environmental conditions in advance of launching a commercial crop.

http://www1.folha.uol.com.br/cotidiano/2014/02/1409225-projeto-propoe-ao-senado-que-legalize-uso-da-maconha.shtml Projeto prop&#245;e ao Senado que legalize uso da maconha 08/02/2013 Quase 16 mil pessoas querem que o Senado vote projeto de iniciativa popular para regulamentar o uso recreativo, medicinal e industrial da maconha. Se o número de apoiadores da proposta chegar a 20 mil, o projeto começará a tramitar no Congresso. A proposta prevê legalizar o consumo da maconha, como já ocorre com bebidas alcoólicas e cigarros. Também permite o cultivo caseiro, o registro de clubes de cultivadores e o licenciamento de estabelecimentos de cultivo e venda no &quot;atacado e varejo&quot;. Os autores defendem sua aprovação com o argumento de que mercado não regulado da maconha gera &quot;violência, crimes e corrupção&quot;. Desde o ano passado, o site do Senado permite, no portal e-Cidadania, que qualquer pessoa sugira projetos ao Congresso. Mas, para que tramitem, é preciso do apoio mínimo de 20 mil internautas. O projeto fica quatro meses no site. Se atingir o número mínimo, vai para análise da Comissão de Direitos Humanos da Casa -que tem a prerrogativa de não deixá-la tramitar ou transformá-la em uma proposta legislativa real.

Cultivadores de polêmica10/02/2014 | 06h04 Membros do movimento Growroom optam pelas plantações domésticas de maconha Participantes preferem horta em casa para evitar se expor recorrendo ao produto de traficantes http://zerohora.clicrbs.com.br/rs/geral/noticia/2014/02/membros-do-movimento-growroom-optam-pelas-plantacoes-domesticas-de-maconha-4414755.html Kamila Almeida kamila.almeida@zerohora.com.br Há 12 anos, um grupo vem se organizando no Brasil, clandestinamente, para plantar maconha, em uma espécie de agricultura de subsistência. São três os objetivos: fugir dos traficantes, consumir um produto mais puro e engrossar a luta pela descriminalização. Estreando no cultivo de uma horta, um universitário da zona norte de Porto Alegre tem três minipés de maconha germinando no quarto, em vasos de dois litros, cercados por dois ventiladores improvisados com componentes de computador, um exaustor e lâmpadas fluorescentes. – Pode tocar, com cuidado. É como se fosse meu cachorrinho, meu bicho de estimação – alerta o estudante que não quer se identificar. O hobbie de growers (cultivadores, em inglês) como ele deu origem ao Growroom, um grupo de ativistas que luta pela descriminalização da cannabis e também pelo cultivo caseiro como uma forma de redução de danos e rompimento com o tráfico de drogas. Foi este o coletivo que chamou a atenção da polícia depois de divulgar na internet o vídeo de uma competição de maconha realizada em dezembro, na Capital. Com a repercussão, os participantes passaram a ser investigados pelo Departamento Estadual de Investigação do Narcotráfico (Denarc). Nesta semana, algumas pessoas serão ouvidas. Para os growers, o sigilo é o princípio maior. A divulgação das imagens foi um deslize que dividiu opiniões no movimento. A intenção foi dar segmento ao ativismo e fazer circular entre os membros uma recordação do evento. – Sabemos que é ilegal e que não podemos nos expor. Não falamos disso com ninguém que não seja do Growroom, não oferecemos e não vendemos nem para os nossos melhores amigos – garante um deles. Tal discrição levou a reportagem de Zero Hora a cumprir algumas exigências para poder visitar a casa do jovem na Zona Norte. De olhos vendados por óculos com película preta, a repórter chegou de táxi a um ponto de encontro combinado e seguiu no carro do ativista até o apartamento de classe média onde ele mora sozinho. Depois de todo o mistério no percurso para que não houvesse pista de onde fica a casa, o que se revelou foi uma estufa artesanal com dois caixotes montada no quarto. Ele se autorrecrutou para a tarefa depois de descobrir que, com o plantio, poderia se livrar da compra da droga no mercado negro. A erva foi plantada em 12 de novembro do ano passado e deu os primeiros sinais de germinação sete dias depois. Até agora, nenhuma flor apareceu para que, depois de seca e curada, fosse consumida, o que deve ocorrer em abril ou maio. Universitário mantém estufa artesanal para cultivo da erva em apartamento Fundado em 2002, o Growroom surgiu depois que um dos cultivadores passou um período estudando na Alemanha e trouxe a ideia de lá para o Brasil. No início, a intenção era de que fosse uma plataforma onde os usuários de cannabis pudessem discutir sobre cultivo como uma forma de redução de danos para si e para a sociedade. Com o tempo, os integrantes transformaram passatempo em militância. A Copa Growroom – onde 26 competidores apresentaram a sua produção – foi a evolução das discussões e de outros encontros informais que ocorriam pelo Brasil desde 2008 com o objetivo de sempre: fumar e trocar ideias sobre o movimento. Segundo eles, o comércio não é permitido nesses ambientes e só são convidados integrantes do fórum – espaço virtual para a troca de experiências sobre o plantio da erva. Justificam que, dificilmente, um cultivador conseguirá comercializar a droga, pois seria necessário um espaço muito amplo para a produção de maconha gerar excedente. Um dos participantes do grupo, do centro do país, explica que a erva prensada, vendida em bocas de fumo, é muito mais densa do que a flor, para ficar mais fácil transportar grandes quantidades. Cada flor resulta em um cigarro de até 1,5 grama. As melhores produções chegam a resultar em 200 gramas do produto, o que caberia em um pote médio. Como a colheita é feita a cada três meses, isso daria uma fração de 2,2 gramas de maconha para o consumo diário. – O cultivador é indiciado como traficante, na maioria das vezes, mas é só alguém buscando alternativa de se autoabastecer sem precisar comprar uma erva com qualidade duvidosa, que faz mal para a saúde e para a sociedade. Quando cultivo dentro de casa não vou para a boca de fumo, não estou influenciando uma criança a pegar uma arma – disse um dos administradores do fórum, com mais de 50 mil inscritos. A proposta tende a atrair gente com médio e alto poder aquisitivo, com Ensino Superior, que sabe dos riscos que correm por praticarem algo ilegal, mas os assumem pela causa. Luís Fernando Tófoli, psiquiatra e professor da Universidade Estadual de Campinas (Unicamp), explica que existem mais de 70 tipos de cannabinoides (substâncias químicas produzidas pela maconha) descobertas até agora. O mais famoso é o Tetrahidrocanabinol (THC), que deixa o cérebro mais ativo. Recentemente, catalogou-se o canabidiol (CBD), que estimula o relaxamento. Tófoli crê que a proibição da maconha trava as pesquisas científicas sobre o assunto. – O THC e o CBD possuem fortes propriedades medicinais, principalmente, para epilepsia e dor. O problema com o proibicionismo é que, como no mercado se busca a “chapação”, o efeito agudo, mais ligado ao THC, os traficantes acabam reforçando cada vez mais variantes da planta rica em THC. Não se importando com o CBD, eles alteram o aparente equilíbrio natural que a planta tem, tornando-a mais perigosa – disse o médico. Mas atenção: não é por ser uma planta, algo natural, que não oferece riscos, principalmente para os consumidores menores de 21 anos. Com a regulamentação, a ideia é minimizar os riscos e maximizar os benefícios, diz o psiquiatra. Com ou sem uma ideologia associada, o cultivo de maconha é crime no Brasil. Emílio Figueiredo, consultor jurídico do Growroom, explica que o Recurso Extraordinário 635659 está tramitando no Supremo Tribunal Federal desde 2011 para tentar derrubar o artigo 28 da Constituição, fazendo com que ninguém mais seja criminalizado por consumir, portar ou cultivar maconha para o próprio consumo. O documento pode ser votado ainda este ano. O debate ganhou força pela recente legalização do uso, da produção e da venda da erva no Uruguai e no Colorado (EUA). – A lei diz que é crime portar droga. O recurso diz que a lei não pode incriminar alguma coisa que envolve a intimidade da pessoa, a liberdade – disse Emílio. O advogado chama a atenção para o fato de a sutileza da lei girar em torno da intenção da pessoa que estava praticando o ato quando foi pega: se portava e plantava para consumo ou para venda. O promotor João Pedro de Freitas Xavier, coordenador do Centro de Apoio Criminal do Ministério Público Estadual, reitera que crime é crime, não importa a intenção. O promotor alerta para o perigo da disseminação do vício na sociedade. – O consumo de drogas, mesmo que para fins recreativos, é ilegal. É passível de ser caracterizado como tráfico – esclarece o promotor. Responsável pelo inquérito que investiga o que aconteceu em dezembro, em Porto Alegre, o delegado Mario Souza, do Departamento Estadual de Investigação do Narcotráfico (Denarc), explica que será averiguado se houve ou não crime naquele dia. – Uma coisa é o movimento pregar uma ideia, trazer o plantio como pauta. O que está sendo averiguado é o que ocorreu no sítio, se será caracterizado ou não como tráfico. O principal elemento de investigação é o vídeo que eles publicaram na internet e, ao que tudo indica, retiraram depois – disse Souza. O que diz a lei - Em vigor desde 2006, a Lei 11.343 prevê punições distintas a usuário e traficante. Quem é descoberto portando ou plantando drogas tem de assinar um termo circunstanciado. A pessoa pode ter de prestar serviços à comunidade e receber uma medida educativa, que prevê a obrigatoriedade de frequentar um programa ou curso. - Se um grupo de amigos for pego fumando o mesmo cigarro, enquadra-se em uso compartilhado com pena prevista de seis meses a um ano de reclusão, que pode ser revertida em prestação de serviços comunitários. - Já a quem comercializa drogas a lei atribui pena entre cinco e 15 anos de reclusão por tráfico. CLIPPING http://www.alagoas24horas.com.br/conteudo/?vCod=189561

Político decide legalizar canábis inspirado por menina de 4 anos A criança sofre de uma paralisia grave, cujos sintomas poderiam ser atenuados com um medicamento derivado da canábis Por: Redacção / MM | 2014-01-24 11:10 http://www.tvi24.iol.pt/503/internacional/cannabis-marijuana-menina-georgia-eua-tvi24/1531256-4073.html Um político da Geórgia, nos Estados Unidos, decidiu avançar com um projeto de lei para legalizar um medicamento derivado da canábis, depois de visitar uma menina de quatro anos, na semana passada. A criança sofre de uma paralisia grave, com sintomas bastante severos, que poderiam ser atenuados com tal medicamento. «Sou um defensor improvável desta causa. Nunca fumei canábis na minha vida e nunca usei drogas. Mas visitei Haleigh Cox, a filha de um dos meis eleitores. Em resultado de ver a sua dor e sofrimento, com 100 convulsões por dia e percebendo que um remédio podia atenuar isso, fui obrigado a mudar de opinião», disse Allen Peake, em declarações telefónicas ao «Tje Huffington Post». O medicamento em causa é cannabidiol, um componente não-psicoativo da planta de canábis. «Se Haleigh fosse minha filha ou minha neta, eu estaria movendo céus e Terra para ter a certeza que o medicamento ficaria disponível. É assim que temos de olhar para ela: é a filha de alguém. Vou usar cada grama da minha influência política para fazer passar esta lei», acrescentou Peake. O projeto de lei que Peake está a preparar ressalva que a legalização visará apenas o cannabidiol e será muito restrito e «muito regulamentado». Fumar canábis não será permitido em qualquer circunstância.

05.02.2014 Fernandes sanciona lei que auxilia dependentes químicos a ter tratamento http://www.otaboanense.com.br/noticia/11703 Um grande passo para o tratamento de usuários de drogas do município de Taboão da Serra foi dado no último mês. O prefeito Fernando Fernandes sancionou, em 19 de dezembro, a Lei 2.189, de autoria do vereador Pastor Eduardo Lopes, que autoriza a Prefeitura a firmar parceira com clínicas especializadas e com entidades governamentais, ou não, para o tratamento de moradores que sejam dependentes químicos. Com a Lei, clínicas e organização, não apenas de Taboão da Serra, como também de outros municípios, serão credenciadas e receberão auxílio da Prefeitura para realizar o trabalho de desintoxicação dos dependentes. O tratamento será concedido a moradores cadastrados e atendidos pelos sistemas municipais de Saúde e de Assistência Social. Segundo o prefeito Fernando Fernandes, a dependência química é uma questão de Saúde Pública, pois é uma doença grave que exige tratamento e que pode haver recaídas. Para que essas recaídas não ocorram, uma rede será criada para auxiliar estas pessoas. “Após sair da clínica, os usuários terão acompanhamento médico, psicológico e social. Eles farão cursos de qualificação profissional, serão auxiliados na reinserção no mercado de trabalho e terão preferência no Programa de Aperfeiçoamento Profissional (PAP)”, declarou. Para o vereador Eduardo Lopes, esta conquista beneficiará inúmeras entidades e famílias, em especial as mais carentes. “Boa parte dos tratamentos de dependentes são custeados por entidades, como igrejas, ou pela família, o que não é o caso da grande maioria, já que os pais, em geral são assalariados e pagam aluguel”, disse. “Através deste projeto teremos ferramentas e mecanismos para auxiliar usuários de drogas e suas famílias, fazer programas de recolhimento e assim encaminhar, a toque de caixa, estas pessoas para clínicas que estarão credenciadas” – afirmou. O vereador Eduardo Lopes comemorou a sanção da Lei porque o poder público não ficou omisso em relação à pandemia das drogas. “O prefeito Fernando Fernandes teve um olhar muito sensível, pois ele sabe que é possível tratar e curar esta patologia, ressocializar e fazer com que estes dependentes químicos, que amanhã serão ex-dependentes, se tornem grandes referências dentro do município”, falou.

Policial - 06/02/2014 - 16:57 Motorista é preso após fumar maconha na frente de posto policial http://www.capitalnews.com.br/ver_not.php?id=259145&ed=Policial&cat=Not%C3%ADcias A Polícia Civil de Coxim prendeu na noite dessa quarta-feira (5) um homem que transportava 13 quilos de maconha na rodovia BR-163. Wellinton Santos de Amorim, de 24 anos, passou em frente ao posto da Polícia Rodoviária Federal (PRF) fumando um cigarro de maconha. Os policiais, percebendo o forte cheiro, ordenaram que o carro parasse e encontraram tabletes de maconha que pesaram 13 quilos e 800 gramas. De acordo com informações do site Dourados News, o motorista contou aos policiais que trabalhava em um lava jato de Mato Grosso e que queria ganhar dinheiro fácil. Wellinton foi encaminhado à Polícia Civil de Coxim e deve responder por tráfico de drogas. Fonte: Carolina Fasolo - Capital News (www.capitalnews.com.br)

Photo by The Daily Beast Written byAbby Haglage Caitlin Dickson 02.03.14 http://www.thedailybeast.com/articles/2014/02/03/welcome-to-the-jungle-pot-tourism.html#url=/articles/2014/02/03/welcome-to-the-jungle-pot-tourism.html Welcome to the Jungle: Pot Tourism Those Rocky Mountains sure are nice and…high, but they’re not the only natural wonder visitors are coming to explore in Colorado. "Birthday girl gets greens!" declares Mike Eymer, before passing his large bong from one end of the white Hummer limousine to Jenna, the quiet blonde sitting at the other. She lights up timidly, gulps down and passes it to her mother, Carol, as she exhales, filling the back of the limo with a cloud of smoke. Carol, who lives in Florida, decided to surprise Jenna for her 22nd birthday by flying her from Oregon, where she goes to college, to Denver for a marijuana tour. "The first clue was my landing time," says Jenna, her eyelids already drooping after one hit. "Her flight got in at 4:20," says Carol smiling. Jenna and Carol are two out of the four day-trippers (not including us) on the inaugural Colorado Cannabis Tours, of the many groups attempting to capitalize on Colorado's brand new, legal recreational marijuana industry. There’s a strong and convincing contingent of groups—like Eymer's version, which at $120 per person is the least expensive—who claim to be “Colorado’s First Cannabis Tour.” The most popular, thanks to an Anderson Cooper special, is Rocky Mountain High Tours, offering a luxury limousine ride, and a gourmet lunch in effort to cater to the “discrete, discriminating cannabis connoisseur.” There’s also 420tours.com, a group differentiating itself with specific themed tours like a Valentine’s Day “Marijuana Love” tour, “St. Patrick’s Day green tour” and this past weekend’s #StonerBowl-themed excursion, featuring free samples of weed and a private viewing party for the big day. “Spend ‘The Big Game Weekend’ in Denver experiencing both our legal cannabis industry and the excitement over the Broncos’ first trip to the big game since 1998,” the description on the web site reads. The Colorado Tourism industry declined to comment on the weed wheels rolling through town, but released a statement that reads: “The Colorado Tourism Office has positioned Colorado as a premier four-season destination and the organization has no plans to use the legalization of the drug to promote the state.” *** We first meet Eymer in downtown Denver at the Cheba Hut, a Quiznos-like Colorado chain where the sandwiches are named after strains of weed like Jamaican Red, Chronic and Kush. (A munches stop, for sure.) The bearded and shaggy-haired 30-something man is dressed head-to-toe in denim, an 'I Heart NY' shirt peeking out from under his paisley cowboy button down. He and his tour group—Jenna, Carol plus Mariah and Gypsy, two forty-something Texans in town for a "girls weekend”—have already finished eating their sandwiches by the time we arrive. They’re ready to carry on with the tour, which includes an overview of the industry, via stops at a dispensary, a glass blowing studio, and a grow house. "Let me know when you're ready to light up so I can roll up the window," says Lori, our blonde, cheerful limo driver. "Not that I don't wanna get high with you, but I can't." The bong changes hands rotating clockwise around the back of the limo as we make our way to our first destination. As the Colorado law is so new, its stipulations still aren't fully understood. Eymer figures that if the windows are rolled up while he passes the bong between destinations, that’s not technically public consumption. This philosophy quickly transforms our ride into a long, white roving chimney. Eymer points to a pot leaf decal on the window. "That could be a liability." The bong changes hands from Carole to Mariah and then Gypsy, rotating clockwise around the back of the limo as we make our way to our first destination. Green Solutions was one of Denver's 17 medical dispensaries to switch over to recreational sales in time for the January 1st debut. Twenty-five days after opening its doors to the pot-smoking public, Green Solutions still has a line that extends out into the parking lot. Our initial embarrassment over pulling up to the popular dispensary in a white Hummer limo quickly dissipates as we are greeted by friendly fellow customers. "This is the nicest shop in town," a regular named Jose tells us as we join him in line. The 22-year-old Chipotle cook says he comes to Green Solutions five times a week. "It's a Willy Wonka factory in there." To us, it’s more like a Starbucks for stoners. We follow the line inside through a quiet, dentist office-like reception area where IDs are checked. Miley Cyrus plays on surround-sound as customers peruse the merchandise (ashtrays, t-shirts, pot leaf-shaped chess sets) and watch six different live streams of the marijuana plants at Green Solution’s growhouse on a flat screen TV, while waiting to be individually escorted around the room by a smiling "budtender.” Pipes, hash oils and all kinds of edibles—from cookies to sour candies to granola—sit behind a glass case like pre-made sandwiches. A separate display featuring actual weed is organized by strain (like alcohol with labels such as “top shelf” and “private stock” with a picture of each the plant, its THC, THCV and CBD content, a description of its taste and high, and a sample nugget. (Green Solution’s hallmark strain, the “Presidential Kush,” for example, is a sativa dominant with a tropical taste and lethargic high.) A separate cashier next to the checkout counter rings up “call ahead” orders. “I feel like such a badass,” says Gypsy, as the limo pulls out of the Green Solutions’ parking lot and onto the highway, the Rocky Mountain’s disappearing behind a cloud of smoke as she and the rest of the tourists sample their legally purchased goods. (They are not included in the price of the tour.) The whole “education” aspect of the tour wears thin as soon as it begins. Anyone that agrees to ride around hot boxing a limo for three hours has probably smoked marijuana before. Even those that haven’t tried it likely already know what it is. Unless you have a fascination with how cannabis grows, there isn’t much more to learn. Plus, almost all of the grow rooms in Colorado are currently off-limits to the public. Some offer media access, and Medicine Man—to the group’s elation—is one of them. “You guys have no idea how lucky you are to see this,” a giddy Eymer exclaims, making clear that he is just as much a tourist in this situation as the rest of us. (A grow visit is always included in the price of Eymer's tour, but Medicine Man's upscale facility was only made available on this occassion because we were riding along.) As Eymer runs around taking photos, Elan Nelson, Medicine Man’s business consultant of strategy and development, shows us The Green Mile: what feels like a never-ending room filled with fresh, aromatic cannabis plants, glowing from the rows of fluorescent lights overhead. Medicine Man is one of the few dispensaries, both medical and recreational, that has its grow house onsite. And its 20,000-foot, Ikea-like warehouse—protected at all times by an armed guard—is one of the largest and most sophisticated in the area. It’s hard to deny that the tour seemed slightly more than a rip off—especially considering the fact that without our media credentials, the group would not have been given access to the most worthwhile part (though Eymer says he is in talks with Medicine Man to include a tour of their facility at an additional cost). While Eymer would be hasty to quit his day job and try to live solely on the bong-in-limo business, Carol, Jenna, Mariah and Gypsy prove that there is some market for pot tourism—at least for now. Editor's Note: An earlier version of this article misspelled the name of Colorado Cannabis Tour's Founder, Michael Eymer, and failed to mention that a grow tour is always included in the cost of one of Eymer's tours. Also, the total price of the tour was incorrectly cited as $200; the tour is $120.

Study: Cannabis Extracts Rich In Cannabidiol (CBD) May Effectively Treat Colon Cancer Drake DormJanuary 9, 2014 http://www.medicaljane.com/2014/01/09/study-cannabis-extracts-rich-in-cannabidiol-cbd-may-effectively-treat-colon-cancer/# As we know, cannabis extracts have been reported to treat a number of ailments. There have been a number of anecdotal success stories, leading to an increased interest in cannabis concentrates (RSO, BHO, Solventless Wax, etc.) as a viable treatment option. Following suit, a recent study adds a bit more fuel to the fire. Partially funded by GW Pharmaceuticals, it suggests that cannabis extracts rich in cannabidiol (CBD) may be an effective treatment for colon cancer. Researchers Treat Colon Cancer In Mice With CBD-Rich Extracts Of course, research has long suggested that medical cannabis could be beneficial for cancer patients. It is often used to counter the negative effects of chemotherapy and studies suggest that the plant could serve as an effective cancer treatment in its own right. “A botanical drug substance (BDS) with high levels of cannabidiol (CBD) inhibited the growth of tumor cells.” Cannabidiol (CBD) seems to carry less of a stigma than tetrahydrocannabinol (THC), a psychoactive cannabinoid that is credited with the “high” associated with cannabis, and shows promise as a way to treat a variety of cancers. In turn, CBD has received a great deal of attention in recent years. Now, a team of researchers from Italy and the UK report that cannabis extracts high in cannabidiol (CBD) can help prevent the genesis and spread of colon cancer in mice. Their study was published in Phytomedicine December 27. According to their results, a “botanical drug substance” (BDS) with high levels of cannabidiol (CBD) inhibited the growth of tumor cells, but not healthy ones. The researchers determined that this action was mediated by activation of the cells’ CB1 and CB2 receptors. Also investigated in the study was the effect of pure cannabidiol (CBD) on colon cancer. According to the data collected, pure CBD inhibited tumor growth also. Interestingly, it did so through activation of the CB1 receptors only. Broad Spectrum Extracts May Be Most Effective Cannabis Treatment It has been suggested that isolating cannabidiol (CBD) from the cannabis plant could offer an effective treatment option for those who do not desire the stigmatized “high.” However, the aforementioned findings suggests a flaw in this logic. Cannabidiol (CBD) certainly has its benefits, but it is not alone in that regard. Tetrahydrocannabinol (THC), cannabichromene (CBC), tetrahydrocannabivarin (THCV), and the remaining cannabinoids have each been linked to a variety of therapeutic benefits in their own right. Terpenes found in cannabis are believed to improve its effectiveness as well. Accordingly, an extract that incorporates each constituent of the cannabis plant is likely to provide the best relief. Of course, a different ratio of cannabinoids will be necessary for each individual, but that is another conversation altogether.

http://seekingalpha.com/article/1997351-gw-pharmaceuticals-ceo-discusses-f1q14-results-earnings-call-transcript?source=google_news GW Pharmaceuticals' CEO Discusses F1Q14 Results - Earnings Call Transcript Feb. 5, 2014 7:15 PM ET| by: SA Transcripts About: GWPH Executives Steve Schultz – VP, IR Justin Gover – CEO Stephen Wright – Director, Research and Development Adam George – CFO Analysts Ritu Baral – Canaccord Genuity Josh Schimmer – Piper Jaffray Joseph Schwartz – Leerink Partners Phil Nadeau – Cowen & Company Samir Devani – WG Partners Bert Hazlett – ROTH Capital Partners GW Pharmaceuticals Plc (GWPH) F1Q14 Earnings Call February 5, 2014 8:00 AM ET Operator Greetings and welcome to the GW Pharmaceuticals’ First Quarter 2014 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. (Operator Instructions). As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Steve Schultz, Vice President of Investor Relations. Thank you, sir. You may now begin. Steve Schultz Welcome and thank you for joining us on the call today. Again, my name is Steve Schultz; I’m the Vice President of Investor Relations at GW. And I’m based in the United States. Here with me today are Justin Gover, GW’s Chief Executive Officer; Chris Tovey, our Chief Operating Officer; Dr. Stephen Wright, our Director of Research & Development; and Adam George, our Chief Financial Officer. We hope you’ve had a chance to review our press release and the 6-K which were issued earlier today. These documents provide additional details of the company’s first quarter financial and operating results. As a reminder, during today’s call we will be making certain forward-looking statements. These statements reflect GW’s current expectations regarding future events, including but not limited to statements regarding financial performance, clinical and regulatory activities, including the regulatory clearance of our products, timing of product launches and statements related to market acceptance and commercial potential. Forward-looking statements involve risk and uncertainties, and actual events could differ materially from those projected herein. A list and description of the risks and uncertainties with an investment in GW can be found in the company’s filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of today’s date. I’ll now turn the call over to Justin Gover, GW’s Chief Executive Officer. Justin Gover Thank you, Steve, and welcome to all those who are able to join us today. And welcome to GW’s new investors from our recent follow-on offering. On today’s call I will briefly review our recent progress, Dr. Stephen Wright will provide a more detailed update on our Epidiolex Product Development Program and Adam George will provide an overview of the financial highlights for the quarter. At the conclusion of our prepared remarks, we will open the line for questions. The last few months have been hugely significant for GW. It is no exaggeration to say that the company has transformed in this period from an investment proposition focused almost wholly on our product Sativex into multi-product platform company with a highly promising and exciting orphan drug opportunity in the field of childhood epilepsy. The emergence of our Orphan Pediatric Epilepsy Program, with our product candidate Epidiolex results from the coming together of both pre-clinical science and clinical case studies. GW has carried out pre-clinical research into the potential of cannabinoids in the treatment of epilepsy over the last six years, which has showed cannabinoids, CBD and CBDV to have significant potential as anti-epileptic drugs. In addition, wealth of clinical case stories, have emerged from the U.S. with increasing frequency over recent months, which provide apparently striking examples of the effects of CBD in reducing seizures in young children with epilepsy. It is clear from all our discussions with the U.S. Medical Community that the specialist physicians responsible for the care of these children want a FDA approved, appropriately tested medicine that they have confidence in prescribing. This was perfected illustrated by Dr. Elson So, President of the American Epilepsy Society, in his recent Op-Ed piece in the Miami Herald. We believe that Epidiolex has the potential to meet the significant unmet medical need. Our strategy is to concentrate initially on two orphan indications, Dravet syndrome and Lennox-Gastaut syndrome. Each of these syndromes represents rare, severe, infantile onset drug resistant epilepsy conditions, with an estimated prevalence in the U.S. of 5,000 to 6,000 children for Dravet and approximately 14,000 to 18,000 for Lennox-Gastaut. November 2013, GW received orphan drug designation from the FDA for Epidiolex for the treatment of Dravet syndrome. In addition, we recently applied to the FDA to obtain orphan drug designation for Epidiolex – for the treatment of Lennox-Gastaut syndrome. With the new funds raised in our successful $101 million follow-on offering last month, GW now has the financial strength to accelerate the Epidiolex Development Program and specifically to conduct Phase 2 and Phase 3 trials in both Dravet syndrome and Lennox-Gastaut, while retaining global commercial rights to the product. Well, on the topic of our offering, we are very pleased to have attracted such a substantial expression of interest in the financing. In particular we are proud that many of the investors in this financing comprise leading healthcare institutional investors in the United States. Of course, in addition to our epilepsy program, GW continues to progress Sativex. Sativex is the world’s first plant-derived cannabinoid based prescription medicine, which is currently approved for use in 25 countries in Europe, EU to multiple sclerosis. Specifically with respect to the United States, Sativex is currently in late Phase 3 clinical trials with the FDA for cancer pain, and we expect initial top-line data from at least one of the Phase 3 trials towards the end of this year, with submission of an NDA in 2015. In addition, we are also pursuing the MS Spasticity Indication in the United States and recently submitted a request to the FDA for special protocol assessment for our proposed single-additional Phase 3 trial. We are currently in set-up with this trial and expect it to start in the second half of this year. Last month, we also expanded our partnership arrangements with Sativex to include Latin America, with the signing of an agreement with Ipson. Ipson is a specialty-driven pharmaceutical company headquartered in France with revenues of greater than €1.2 billion and with a particular strength in neurology that represents an excellent fit for Sativex. Beyond all of this, GW’s proprietary cannabinoid platform has generated active clinical stage pipeline programs in ulcerative colitis, type II diabetes, schizophrenia, and an additional orphan development program in glioma. Please note that all non-Sativex pipeline products are funded completely by GW and GW retains all rights to commercialize any and all products that evolve from these programs. As you can see, there is a great deal of activity at GW at the moment. And for some more detail on the epilepsy program, I will now turn to Stephen Wright. Stephen? Stephen Wright Thank you, Justin and good day everybody. I will start my comments by explaining the activities currently being undertaken to treat children with refractory epilepsies with Epidiolex and the FDA approved investigator led INDs. And will then turn to our own formal development plans. GW’s clinical experience with Epidiolex in the field of pediatric epilepsy began with a request over one year ago from the treating physician of two children in the United States with drug resistant early onset epilepsy. Both children have so far received treatment under FDA individual INDs with Epidiolex for over six months. According to the most recent reports from the treating physician, she has observed seizure reduction up to 90% and subsequent improvement in behavior and cognitive function and has also noted that Epidiolex has been well tolerated in chronic use. Since this initial request, GW has been approached by Epileptologists from across the United States and indeed across the world to find out more about the prospects of using Epidiolex. Several of these independent physicians have applied to FDA to obtain Epidiolex under expanded access INDs in order to prescribe the product to selected patients. To date, a total of seven of these expanded access INDs have been granted by the FDA to independent investigators allowing treatment of a total of approximately 125 pediatric epilepsy patients with Epidiolex. The majority of these patients suffered Dravet and Lennox-Gastaut syndromes, but the list of children also comprises a range of other pediatric epilepsy syndromes. The first patients at two sites in New York and San Francisco began receiving treatment during the week before last. INDs each of these sites allow for the treatment of 25 children per site. We understand from the two physicians that approximately 12 children are currently taking Epidiolex with the remainder expected to begin treatment over the coming weeks. It is our expectation that all 50 of those children across the two sites will have become treatment by the end of March, through an ongoing sequence of regular enrollment through February and through March. Approximately three quarters of these initial 50 patients have Dravet syndrome or Lennox-Gastaut. An additional physician site is expected to commence treatment of its 25 patients around the end of March and the remaining 50 patients to other sites are expected to commence treatment around mid-year after receipt of the necessary site licenses from the drug enforcement administration. Since the beginning of 2014, a number of additional U.S. physicians have submitted similar expanded access INDs to the FDA. Under this expanded access IND program, the physicians will collect regular treatment data on seizure frequency, Epidiolex dosing, the use of concomitant antiepileptic medication, adverse events, and other relevant clinical measures. We expect that meaningful data on an initial cohort of patients should be available around the middle of the year with additional data on these patients as well as on the remaining IND patients to follow during the second half of this year. We expect these INDs will generate important safety and tolerability information as well as initial clinical evidence to support the use of Epidiolex across a number of distinct treatment resistant pediatric epilepsy syndromes. Turning now to our formal regulatory development strategy. GW intends to develop Epidiolex for the treatment of both Dravet and Lennox-Gastaut syndrome. Working with some of the leading pediatric epilepsy specialist in the United States, GW has proposed an investigational plan to the FDA for Epidiolex in Dravet syndrome and we expect to hold a pre-IND meeting in the near future. Following this meeting, we intend to submit an IND to the FDA in the first half of 2014 and then to commence an initial clinical trial in the second half of this year. We’ve proposed this initial trial via two-part randomized double-blind placebo-controlled trial of single and multiple doses of Epidiolex to treat Dravet syndrome in children who are being treated unsatisfactorily with other anti-epileptic drugs. Part one comprises the pharmacokinetic and dose finding elements of the trial. Part two is a placebo-controlled extension which will compare the effect of Epidiolex with that of placebo. GW plans to use the results of this initial study to inform discussions with the FDA regarding the designs of additional efficacy and safety trials that could serve as the basis for future NDAs for Epidiolex in both Dravet and Lennox-Gastaut syndromes. Our intention is to commence pivotal trials in 2015. Our objective working with FDA is to establish Epidiolex as the leading cannabinoid based medicine for the treatment of childhood epilepsy disorders through sound, credible and reliable scientific evidence. I note that that while we would like to see the shortest path to approval for Epidiolex, you should assume that GW will be required to go through the normal development and regulatory path with FDA. Needless to say, we will seek every opportunity to minimize the timelines required to submit the initial orphan NDA and would also hope to be in a position to apply for breakthrough status during the course of the development program. Moving on now from Epidiolex. GW has a second product candidate, GWP42006 which features CBDV cannabidivarin, as the primary cannabinoid. CBDV is structurally related to CBD and has also shown anticonvulsant effects across a range of invitro and invivo models of epilepsy. I would particularly like to draw your attention to a very recent publication showing that CBDV suppresses epilepsy associated gene expression in association with significant anticonvulsant effect providing potential for the development of important genetic biomarkers for efficacy in epilepsy. Very exciting findings indeed. We’ve recently completed dosing in a Phase 1 dose escalation single and multiple dose pharmacokinetics and tolerability clinical trial for CBDV. Results are now in data management, and we expect to issue a release with more information about this study in the first half of 2014. From what we already know, I can say that the safety profile of CBDV looks wholly reassuring as there were no serious or severe adverse events during the Phase 1 trial, nor any withdrawal from the trial due to adverse events. Our current expectation is that we will be advancing plans during the second half of 2014 for CBDV to commence a Phase 2 proof of concept trial. While our epilepsy program remains at the forefront of our pipeline activity, it is important to remember that GW is approaching some key milestones for Sativex and also has several other exciting pipeline programs in progress, each of which is supported by promising pharmacology. For Sativex, as Justin mentioned earlier, we expect initial top-line Phase 3 cancer pain data towards the end of this year and we also expect to commence a U.S. targeted Phase 3 multiple sclerosis spasticity trial in the second half. With respect to our earlier stage pipeline, the key areas for activity are as follows. Firstly, we’re close to completing a Phase 2A trial in the treatment of ulcerative colitis for the botanical drug product GWP42003 which features CBD as its primary cannabinoid. Data from this trial is expected around mid-year. Second, we expect to commence a Phase 2B dose ranging trial in the first half of 2014, in the treatment of type-2 diabetes for GWP42004 which features THCV as the primary cannabinoid. Third, we expect to commence a Phase 2A trial in the first half of 2014 in the treatment of schizophrenia using GWP42003. And fourthly, we recently commenced a Phase 1B/2A trial in the treatment of recurrent glioblastoma multiforme, an orphan disease, for a product candidate which combines GWP42002 with GWP42003. In summary therefore, we have a very busy program of R&D activities at present and expect progress across all major areas of the pipeline during 2014. Let me now turn the call over to Adam for the financial review. Adam? Adam George Thank you, Stephen. I intend to provide some general comments on today’s Q1 financial results. A more detailed discussion of our results is given in the press release that we issued earlier today. GW presents its financial results in accordance with International Financial Reporting Standards or IFRS accounting rules, in British pounds sterling, for convenience purposes U.S. dollar equivalence to certain key numbers. Today we’re reporting on the three months ended 31, December 2013. I’ll start with revenues. Total revenues for the quarter were £7.5 million or $12.4 million compared to £5.2 million in Q1 2013, a revenue increase of £2.3 million. This increase is due to two factors. A £1.7 million increase in research and development fees increased to £6.4 million or $10.5 million reflecting progress with the recruitment of patients into the Otsuka-funded Phase 3 cancer pain trials as well as the cost of setting up the MS Phase 3 trial that we expect to start later this year. Sativex revenue of £0.8 million or $1.3 million increased from £0.2 million in the prior period. This reflects the fact that the prior period was impacted by £0.7 million provision for rebate due to Almirall following the adverse pricing decision in Germany in early 2013. In market sales volumes via partners, Sativex increased by 36% over the prior period. This reflects continued growth in Germany plus a strong start in Italy which launched recently. Next, R&D spend, total R&D expenditures for the quarter increased by 43% to £9.2 million or $15.2 million from £6.4 million in the three months until December 31, 2012. This is made up of two elements, the first being the Otsuka-funded Phase 3 R&D-spend that I referred to earlier, which increased to £6.4 million or $10.5 million. Otsuka continue to fund approximately 70% GW’s total R&D spend, but we’d expect this proportion to reduce in the future as we invest more of R&D funds into our pipeline programs. In this quarter, GW funded-spend increased £2.8 million or $4.6 million, the increase is linked to the completion of the CBDV Phase 1 study, they completed dosing recently plus the start-up cost of the glioblastoma study that started in the last quarter. Management and administration spend of £1.5 million or $2.5 million was £0.7 million higher than the prior period. £0.5 million of this increase reflects growth in the provision that we hold for future payroll taxes payable by GW on future stock share auction gains driven by the significant increase in our share price during the period with the remaining increase in costs being cost associated with our NASDAQ listing. This all resulted in a loss before tax for the three months of £3.5 million or $5.8 million which compares to a loss of £2.4 million for Q1 2013. Turning to tax, the £0.7 million or $1.2 million tax credit recorded in this quarter reflects the research and development tax credit that we will claim from the U.K. Tax Authority by the end of the 2014 financial year in respect of R&D spend incurred in this quarter. In the prior period of 31 December 2012, we recorded a £4.4 million tax credit which included a number of one-off items resulting from agreements reached with the U.K. Tax Authority in the first quarter of 2013, these items have not been repeated in this quarter. The net operating cash outflow for the quarter was £2.8 million or $4.6 million compared to £1.7 million outflow in the period ended December 31, 2012. As I’ve already noted, most of this increase is linked to GW funded pipeline research and development spend. We ended the period with cash of £35.2 million or $58.4 million at December 31. Subsequently following the successful completion of our follow-on offering in January, this has been further enhanced by the net proceeds received $94 million giving current cash position approaching £91 million or $150 million. Finally, let me update our 2014 guidance. As I guided in November, we expect continued in-market sales volume growth by our partners to lead to growth for Sativex revenues in 2014. And in terms of milestone income, we continue to expect to receive a $5 million milestone from Otsuka on commencement of the MS Phase 3 study later this year. In terms of R&D spend, I previously guided you to expect GW funded R&D to increase by 40% to 50% this year as we progress a number of clinical stage pipeline programs. Having completed our recent fundraising as per the guidance given in the fundraising prospectus, I now expect this to increase further as the results of planned Epidiolex program spend. In cash flow terms I expect to spend $10 million at the offering proceeds in this financial year. Therefore operating cash outflows plus planned capital expenditure should now result in a cash outflow of approximately $34 million or £21 million for the 2014 financial year. In terms of profitability, we continue to expect to report a loss for the 2014 financial year. The size of that projected loss can be expected to increase in-line with the additional cash spend that I just outlined. Thank you. I would now hand the call back to Justin. Justin Gover Thank you, Adam. GW has had an extremely busy first quarter and look forward to an exciting year ahead during which we expect to update investors on a series of important milestones. With respect to epilepsy we continue to progress, expanded access treatment IND programs throughout the year with initial data being released from mid-’14 onwards. For Sativex, we expect initial top-line Phase 3 data in cancer pain around the end of the year as well as the start of our U.S. MS Spasticity Phase 3 trial in the second half. We also have numerous clinical trials expected across the pipeline with the next Phase 2 data coming from our ulcerative colitis trial. Our model in the past has been to develop cannabinoid-based therapeutics and partner them out as we did with Sativex. However, much has changed over the recent months and we are very excited about the opportunity to retain the full commercial rights to our orphan epilepsy program and leverage that opportunity to the benefit of our shareholders. Finally, as demonstrated by our 15 years of experience dedicated towards cannabinoid therapeutics and our development and regulatory track record established over this extended period, GW is proud to be at the forefront of cannabinoid science. And we believe that we are the company best positioned to lead the way into the future of the therapeutic class. Thank you again for joining us today. And I’m now able to open the line for questions. I’ll turn back to the operator. Thank you very much. Question-and-Answer Session Operator (Operator Instructions). Our first question comes from the line of Ritu Baral with Canaccord Genuity. Please proceed with your question. Ritu Baral – Canaccord Genuity Good morning. Thanks for taking the question guys. I wanted to ask you about some of the details on the investigator studies for Epidiolex being conducted right now. Specifically, you said that they would – the investigators would be capturing dosing data. What are the parameters for dosing in this trial and dose escalation, what are they allowed to do? And what are you – what sort of escalation are you thinking about for the trial that you guys will start in the second half? Stephen Wright Hi Ritu, Stephen Wright here. The dosing recommendations within the investigator led expanded access INDs are all ones which have been agreed with FDA they start at a dose of 2.5 milligrams per kilogram and dose-titrate up to a maximum of 25 milligrams per kilogram, there is a very slight variability between individual INDs. But essentially that’s the top dose that FDA have so far approved within that setting. We’re aiming within our own GW sponsored INDs to explore the same dose range and to one dose range higher than 25 milligrams per kilogram up to 50 mgs per kg. That of course remains a subject for discussion with FDA but that’s our target. Ritu Baral – Canaccord Genuity And do you expect a large degree of variability on the appropriate dose for the patient population? I guess the question is do you expect that certain kids will need a wildly different dose than others? Stephen Wright I mean, I think actually it’s the case with almost every other anti-epileptic drug. There is going to be a range of effective doses that I’m sure that’s correct. And you can probably predict that and the fact that CBD Epidiolex has a relatively low oral bio-availability which almost always means there is going to be variability between subjects in the way they respond to it. Fortunately because we have such a good safety profile, I don’t think that’s of any negative consequence. And actually Epileptologists are very comfortable and very used to the idea that they need to explore dose range in children with epilepsy. Ritu Baral – Canaccord Genuity I see. And the other epilepsy trial – the phase 1 in 42006, what sort of data will we have when you release the phase 1 data, will we have any sort of markers of efficacy? Stephen Wright That study is actually a healthy volunteer. It’s conventional Phase 1 study. So, we do not have any pharmacodynamic markers other than safety. So, what it is, it’s a conventional single dose, single rising dose and then multiple dose pharmacokinetic study. So, we will learn the pharmacokinetics all the normal parameters you would expect, half-life, maximum plasma concentration, time to maximum plasma concentration and so on, both in single dosing and in multiple dosing. And we will be able to link any safety concerns that we might have from the study with the exposure of the volunteers to the drug. So that will then allow us to target an appropriate dose range to move into our proof-of-concept study later this year. Ritu Baral – Canaccord Genuity Got it. And last follow-up and I’ll get in the queue, what differences do you predict in the clinical profile between CBD and CBDV, depending on the work that you’ve done? Justin Gover I think it’s almost certain that we will not be targeting the same types of epilepsy straight off the bat with 42006 CBDV as we are with CBD. So the proof-on-concept with CBDV will be a more conventional approach in complex partial seizures and we will then determine exactly which patient population to go into in pivotal studies with CBDV. So, we don’t at this point have any expectation of a markedly different profile for the one than for the other. But we will almost certainly be exploring different epilepsy subtypes with CBDV than with CBD. Ritu Baral – Canaccord Genuity Great. Thanks for taking the question guys. I appreciate it. Operator Thank you. Our next question comes from the line of Josh Schimmer with Piper Jaffray. Please proceed with your question. Josh Schimmer – Piper Jaffray Hi, thanks for taking the questions. First of all, any sense on the size of the Epidiolex placebo-controlled phase of the Phase 2 study? And when would you expect the randomized portion of that trial to begin? And then last, what’s giving you the confidence now to advance so quickly into a placebo-controlled study, has there been any change in your observations or any new findings that’s driven that? Stephen Wright Thanks Josh, Stephen Wright here again. Very broadly we’re anticipating that there would be 60 patients in each of the two pivotal studies that we’re proposing. And that sample size is based on an assumption of around about 55% responder rate on drug and about 25% responder rate on placebo. Those numbers work in that kind of setting. Of course, we’re yet to determine whether the expectations of FDA for a suitable database size will be met by those proposals and we’ll find that out quite soon. But that’s the way we framed our approach. Do we think, it’s too soon to be going into placebo-controlled trials? The answer is no, we don’t. The pivotal portions of those studies wouldn’t start until the end of this year or the beginning of next year actually more likely. And by that time we will have quite a significant amount of guidance from the expanded access IND open-label data that we’ve seen up to that date. I should point how that the studies that we’ve proposed in start what we called part A, which is a dose ranging pharmacokinetic and safety evaluation. And that part is also placebo-controlled. So, actually the entire body of GW-sponsored clinical trial work under an IND will be placebo-controlled. Josh Schimmer – Piper Jaffray So, and you said two pivotal studies, is that two in Dravet or one in Dravet and one in Lennox-Gastaut? Stephen Wright The current proposal is that we will propose two in Dravet. Clearly, if at some stage, due to accumulation of data FDA became comfortable with a single pivotal study if it was sufficiently compelling or enough, then that would be great. I think it would be injudicious of us to propose that off-straight off the bat right now. Josh Schimmer – Piper Jaffray Got it. And maybe a last question. Can you give us a sense of process or timing in listing what seems to be a pretty absurd scheduling of Epidiolex as a Schedule 1 drug? Who makes the decision to change than scheduling? What has to happen before that? And is there any action or activities from parents, families, or physicians to facilitate that or there is there anything that could be doing? Justin Gover Josh, hi, it’s Justin here. I’ll reflect off Stephen on that one. I mean, it’s obviously a major topic of discussion the whole issue is of course as you well know. I mean, at the end of the day there is a systematic approach to rescheduling. And again just as you’re hearing with respect to our development program. I think for now I think you just have to assume that the scheduling will change on approval of an FDA-approved prescription medicine. I don’t think we can comment beyond that. Obviously we’re well aware that there is a lot of activity. And I’m sure there is discussion within the medical community and other parts of bodies within the U.S. about this. But from our perspective it’s a schedule 1 substance all the sites that we use in the treatment of INDs have Schedule 1 licenses. And in that respect, actually although it is, and you might say maybe absurd but actually the process to work, we are able to go through this licensing process. As you know, children are starting to be started and sponsored studies will be done. As they are with Sativex, Sativex is still Schedule 1 and we were able to navigate through that. So, I don’t think it will harm our own progress. Josh Schimmer – Piper Jaffray Got it. Thanks very much. Operator Thank you. Our next question comes from the line of Joseph Schwartz with Leerink Partners. Please proceed with your question. Joseph Schwartz – Leerink Partners Hi, thanks very much. I was wondering if you could tell us how focused are you on keeping European development at a pace that mirrors the United States and what kind of activities are ongoing outside the US, such as with the EMA? Stephen Wright Joseph, hi, it’s Stephen Wright here. Yes, we are indeed going to be recruiting both within Europe and the United States in our pivotal clinical trials. And we are having preliminary discussions with the EMA during March. Joseph Schwartz – Leerink Partners Okay. And then how are you thinking of going after orphan epilepsies outside the US and EU? Is there any orphan drug exclusivity route in places like Latin America that you can take advantage of? Stephen Wright At this point, our ambitions extend to the EU and to United States. I think you’ve raised a very good point. And clearly, in due course, we need to explore how rapidly we can globalize the opportunity as yet we haven’t fully done that. Joseph Schwartz – Leerink Partners Okay. And then lastly, regarding the GWP42003 and ulcerative colitis, I think that’s a 10-week dose escalation study, and you said you were close to finishing the dosing with data mid-year. I was wondering how did you settle on the 10-week duration and what is the up-titration schedule, was that informed by any of the anecdotal observational studies with CBD-enriched cannabis? How likely do you think it is that patients will be able to get to a meaningful therapeutic dose in that time frame, how have you designed that? Stephen Wright Sure. I mean, firstly the 10-week dosing period. The objective of the study is to induce remission in patients actually who fail to have remission induced by first line of therapy. And in general, I think everyone would accept if you don’t induce remission over 10-week period, that’s a treatment failure. Clearly, if we were looking at the maintenance of remission, we would want much longer exposures. But for the induction of remission, most of this is actually 6-8 weeks. So, I think we’re very comfortable with the 10-week period. In terms of the dose-titration this – the material being used in the ulcerative colitis study for very good pharmacologic reasons contains a small proportion of THC. And it’s actually the THC within the material, THC has desirable properties on gastrointestinal ability. It’s because the presence of the THC that we’re dose-titrating upwards. You’ll appreciate from our experience with Sativex and a lot of Phase 1 experience with CBDX track that we’ve become very familiar with the rate at which dose increases can occur. So, I think we’re very comfortable that we’ve achieved a certain we’re able to achieve both the rapid and appropriate dose titration. I hope that answers your questions. Joseph Schwartz – Leerink Partners Yes, that’s really helpful. Thanks. Operator Thank you. Our next question comes from the line of Phil Nadeau with Cowen & Company. Please proceed with your question. Phil Nadeau – Cowen & Company Hi, thanks for taking my questions. First just a housekeeping question on the 2014 guidance. If I interpreted your comments correctly, it sounds like you’re guiding to a 40% to 50% increase in R&D plus $10 million. Is that correct or did I misinterpret what you said? Adam George This is Adam George. Yes, I have said that we are going to spend $10 million. I wasn’t specific that all of that will be going through the R&D line but the majority of it will be. So, yes, your interpretation is there or there about. Phil Nadeau – Cowen & Company Okay, great. My second question is on the trial design that you discussed for the pivotal trials. I think you said a 55% responder rate on drug, 25% on placebo. I was curious about the placebo response rate. I had thought Dravet was very refractory epilepsy. How would placebo be causing a 25% response rate? How would you be defining response to see that level of response from placebo? Justin Gover The definition of a responder rate is better than 50% reduction in seizure frequency. And I completely agree with you that in general Dravet is thought to be very treatment resistant. However, if you look at occasional published studies for example, with stiripentol in Dravet, there is a distinct placebo response. And our U.S. Chief Investigator Dr. Oren Dubinsky has published some very elegant papers on placebo responses in patients with epilepsy, which I think mean that it would be injudicious of us to predict a very, very low placebo response in the setting of a Phase 3 clinical trial. I think we need to do that and were there then a placebo response of some significance to occur we would be caught with egg in our face and that’s not something we want to be. Phil Nadeau – Cowen & Company I guess the – that’s a very fair point. And I guess the broader question I’m wondering about is – a lot of us are interpreting the data or the press reports about reductions in the seizure frequency from CBD enrichment of medical marijuana. And soon I think we’ll all be interpreting the reduction in seizure frequency we see from the treatment INDs. Should we kind of assume 25% of patients would probably have a reduction in seizure frequency no matter what they got, when we try to interpret these anecdotes or I guess give us some sense of how we should interpret the uncontrolled anecdotes that we see? Justin Gover Yes, no, I don’t think so. And I think the answer is that placebo-controlled clinical trial in a very formal setting with a very fixed primary outcome measure on different animals than what happens in real life and in the clinic. And I hope the two are complimentary when we come to submit our orphan NDA for Epidiolex in Dravet. So, I did mention during the presentation that we are in our view being relatively conservative with our proposals to FDA to the investigational plan. And I think this discussion about the placebo response in clinical trials illustrates exactly that we are being relatively conservative. And we would suggest that that may offer some potential upside if it turns out the placebo response is in fact somewhat lower than that. So, I think that’s how I’d position our – the way we’re powering our clinical trial. Phil Nadeau – Cowen & Company Okay, great, and one last question. You have conducted the survey of patients who have been on CBD-enriched medical marijuana, which has shown a pretty dramatic reduction in seizure frequency for those patients. What I’m actually curious about is just the patient makeup of the survey. If I remember correctly, the vast majority of patients were Dravet with only one or two Lennox-Gastaut patients in the survey. And I’m curious about that. It seems like there’s actually probably more Lennox-Gastaut patients out there than Dravet. So why was the population skewed toward Dravet? Is it something about the age of the kids or the severity of Lennox-Gastaut that means they’re not going on CBD-enriched medical marijuana whereas Dravet is? Stephen Wright You’re making very good point. Can I first look at your first point Nad, because it refers back to my previous answer. If you look at the results found in that published survey, about 64% of the children overall got a better than 50% reduction in seizure rate. That’s more or less what we are aiming at in our clinical trials. So I think that’s a kind of another reference point that we can use. I think 13 out of the 19 children in there were Dravet children. And I think it was tilted towards Dravet children, simply because of the particular interest of the Dravet Foundation actually. And that’s my understanding. And I believe that Dravet Foundation is more active currently than Lennon-Gastaut Foundation. I think that’s probably the simple reason. Phil Nadeau – Cowen & Company Okay, so there’s no reason to think CBD would work less or be less appropriate for a Lennox-Gastaut child than a Dravet child? Stephen Wright No, and there are published case reports out there showing dramatic improvements in Lennox-Gastaut children as well. Phil Nadeau – Cowen & Company Great. Thanks for taking my questions. Operator Thank you. Our next question comes from the line of Samir Devani with WG Partners. Please proceed with your question. Samir Devani – WG Partners Hello everyone. I’ve got a few questions. Just, the first question is for Stephen. Just going back to the seizure dosing for Epidiolex, what sort of adverse events would you expect to see as you approach the NTD? Stephen Wright Honestly minor and non-specific adverse events. We’ve seen zero in the way of target organ toxicity, even at very, very high doses in all toxicology studies. So, we’re talking about things like headache, minor gastrointestinal disturbances that kind of thing Samir. So, nothing I think specific at all. Samir Devani – WG Partners Okay. And just moving on to the non-orphan epilepsy opportunity, what’s the strategy there? Stephen Wright I think the strategy remains to be fully elaborated. Certainly the proof-of-concept with CBDV currently, we’re aiming to target complex partial seizures, probably in adolescence. But even that remains to be fully determined. We believe that that would give us the best, what can I say, that would allow us to reach the fork in the road which gives us the most productive routes then to follow. Samir Devani – WG Partners And then, just finally one bit of housekeeping, in terms of Sativex, I think you had applied for regulatory approval in the Gulf States. I’m just wondering if you can give us an update as to how that’s going. Justin Gover Well, we have regulatory approval in Kuwait that’s done and dusted. And we’re waiting for more regulatory approval in the other Gulf member states. We have had our manufacturing plant satisfactorily inspected by the Gulf coordinating committee. So all the, kind of pieces are in place. Samir Devani – WG Partners Okay. Were we not expecting some milestones from approval in Gulf States or is that no longer the case? Justin Gover There, hi Sameer, it’s Justin here. There is milestone associated with a combination of a couple of Gulf States. But it’s a relatively immaterial milestone. And but, yes, and I mean, the approvals are still expected. Samir Devani – WG Partners Great. Thanks very much. Justin Gover Okay. Operator Thank you. Our next question comes from the line of Bert Hazlett with ROTH Capital. Please proceed with your question. Bert Hazlett – ROTH Capital Partners Thanks. I just have a brief one. Could you remind us of the intellectual property strategy for Epidiolex? Clearly you have orphan drug designation for Dravet. Are there additional strategies in place beyond orphan drug for the individual settings, and if so, could you comment on those? Thanks. Justin Gover Yes, hi, Bert. Thanks. This is Justin here. So, there are a couple of specific use related patents for CBD in the epilepsy therapeutic area, which are going through prosecution right now as well as some IP that relates to the purification and other sort of process steps that are involved in the production of the product. So, there is literature around CBD and epilepsy. So those patents are relatively focused. I think, and it is undoubtedly the case that one of our ambitions is to – is also within the concept of an epilepsy portfolio to be looking not just at Epidiolex and the protections that are provided both by exclusivity in this IP but also thinking more broadly relevant to the previous question actually about the role of CBDV as we move forward which is also well protected. So, I think there is a matrix approach that we’ve taken here which is not the similar to Sativex actually, the Sativex doesn’t have a single key patent, there are various patents around this. But I think it’s probably fair to say that the orphan exclusivity is particularly important for CBD. Bert Hazlett – ROTH Capital Partners And just one follow-up. You have the patents under prosecution. Could you, it’s always a mystery as to how that progresses. Could you comment on the general status? Do you think you’re close to notice allowance or are they in early days in terms of being prosecuted? Justin Gover Our approach for the IP prosecution is over the last 15 years has been attended to use the U.K. Patent Authority as a kind of initial text if you will. And those patents we can get opinions quite quickly and prosecute quite quickly. So, we do have opinions. And so I think you can take it from that the prosecution in the U.S. is continuing on the basis of feedback that we’ve received already from the U.K. examiners. Bert Hazlett – ROTH Capital Partners Okay. Operator Thank you. Ladies and gentlemen, we’ve come to the end of our allowed time for questions. I would like to now turn the floor back over to management for any closing comments. Justin Gover All right, thank you. So, it’s Justin Gover here, just wrapping up. Thank you for all your attention this morning. I hope we’ve been able to clarify some key aspects of the news flow for this year in particular with regards to the evolution of the epilepsy program through the remainder of 2014. And we look forward to updating you in with our second quarter results in a few months’ time. Many thanks. Operator Greetings and welcome to the GW Pharmaceuticals’ First Quarter 2014 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. (Operator Instructions). As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Steve Schultz, Vice President of Investor Relations. Thank you, sir. You may now begin. Steve Schultz Welcome and thank you for joining us on the call today. Again, my name is Steve Schultz; I’m the Vice President of Investor Relations at GW. And I’m based in the United States. Here with me today are Justin Gover, GW’s Chief Executive Officer; Chris Tovey, our Chief Operating Officer; Dr. Stephen Wright, our Director of Research & Development; and Adam George, our Chief Financial Officer. We hope you’ve had a chance to review our press release and the 6-K which were issued earlier today. These documents provide additional details of the company’s first quarter financial and operating results. As a reminder, during today’s call we will be making certain forward-looking statements. These statements reflect GW’s current expectations regarding future events, including but not limited to statements regarding financial performance, clinical and regulatory activities, including the regulatory clearance of our products, timing of product launches and statements related to market acceptance and commercial potential. Forward-looking statements involve risk and uncertainties, and actual events could differ materially from those projected herein. A list and description of the risks and uncertainties with an investment in GW can be found in the company’s filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of today’s date. I’ll now turn the call over to Justin Gover, GW’s Chief Executive Officer. Justin Gover Thank you, Steve, and welcome to all those who are able to join us today. And welcome to GW’s new investors from our recent follow-on offering. On today’s call I will briefly review our recent progress, Dr. Stephen Wright will provide a more detailed update on our Epidiolex Product Development Program and Adam George will provide an overview of the financial highlights for the quarter. At the conclusion of our prepared remarks, we will open the line for questions. The last few months have been hugely significant for GW. It is no exaggeration to say that the company has transformed in this period from an investment proposition focused almost wholly on our product Sativex into multi-product platform company with a highly promising and exciting orphan drug opportunity in the field of childhood epilepsy. The emergence of our Orphan Pediatric Epilepsy Program, with our product candidate Epidiolex results from the coming together of both pre-clinical science and clinical case studies. GW has carried out pre-clinical research into the potential of cannabinoids in the treatment of epilepsy over the last six years, which has showed cannabinoids, CBD and CBDV to have significant potential as anti-epileptic drugs. In addition, wealth of clinical case stories, have emerged from the U.S. with increasing frequency over recent months, which provide apparently striking examples of the effects of CBD in reducing seizures in young children with epilepsy. It is clear from all our discussions with the U.S. Medical Community that the specialist physicians responsible for the care of these children want a FDA approved, appropriately tested medicine that they have confidence in prescribing. This was perfected illustrated by Dr. Elson So, President of the American Epilepsy Society, in his recent Op-Ed piece in the Miami Herald. We believe that Epidiolex has the potential to meet the significant unmet medical need. Our strategy is to concentrate initially on two orphan indications, Dravet syndrome and Lennox-Gastaut syndrome. Each of these syndromes represents rare, severe, infantile onset drug resistant epilepsy conditions, with an estimated prevalence in the U.S. of 5,000 to 6,000 children for Dravet and approximately 14,000 to 18,000 for Lennox-Gastaut. November 2013, GW received orphan drug designation from the FDA for Epidiolex for the treatment of Dravet syndrome. In addition, we recently applied to the FDA to obtain orphan drug designation for Epidiolex – for the treatment of Lennox-Gastaut syndrome. With the new funds raised in our successful $101 million follow-on offering last month, GW now has the financial strength to accelerate the Epidiolex Development Program and specifically to conduct Phase 2 and Phase 3 trials in both Dravet syndrome and Lennox-Gastaut, while retaining global commercial rights to the product. Well, on the topic of our offering, we are very pleased to have attracted such a substantial expression of interest in the financing. In particular we are proud that many of the investors in this financing comprise leading healthcare institutional investors in the United States. Of course, in addition to our epilepsy program, GW continues to progress Sativex. Sativex is the world’s first plant-derived cannabinoid based prescription medicine, which is currently approved for use in 25 countries in Europe, EU to multiple sclerosis. Specifically with respect to the United States, Sativex is currently in late Phase 3 clinical trials with the FDA for cancer pain, and we expect initial top-line data from at least one of the Phase 3 trials towards the end of this year, with submission of an NDA in 2015. In addition, we are also pursuing the MS Spasticity Indication in the United States and recently submitted a request to the FDA for special protocol assessment for our proposed single-additional Phase 3 trial. We are currently in set-up with this trial and expect it to start in the second half of this year. Last month, we also expanded our partnership arrangements with Sativex to include Latin America, with the signing of an agreement with Ipson. Ipson is a specialty-driven pharmaceutical company headquartered in France with revenues of greater than €1.2 billion and with a particular strength in neurology that represents an excellent fit for Sativex. Beyond all of this, GW’s proprietary cannabinoid platform has generated active clinical stage pipeline programs in ulcerative colitis, type II diabetes, schizophrenia, and an additional orphan development program in glioma. Please note that all non-Sativex pipeline products are funded completely by GW and GW retains all rights to commercialize any and all products that evolve from these programs. As you can see, there is a great deal of activity at GW at the moment. And for some more detail on the epilepsy program, I will now turn to Stephen Wright. Stephen? Stephen Wright Thank you, Justin and good day everybody. I will start my comments by explaining the activities currently being undertaken to treat children with refractory epilepsies with Epidiolex and the FDA approved investigator led INDs. And will then turn to our own formal development plans. GW’s clinical experience with Epidiolex in the field of pediatric epilepsy began with a request over one year ago from the treating physician of two children in the United States with drug resistant early onset epilepsy. Both children have so far received treatment under FDA individual INDs with Epidiolex for over six months. According to the most recent reports from the treating physician, she has observed seizure reduction up to 90% and subsequent improvement in behavior and cognitive function and has also noted that Epidiolex has been well tolerated in chronic use. Since this initial request, GW has been approached by Epileptologists from across the United States and indeed across the world to find out more about the prospects of using Epidiolex. Several of these independent physicians have applied to FDA to obtain Epidiolex under expanded access INDs in order to prescribe the product to selected patients. To date, a total of seven of these expanded access INDs have been granted by the FDA to independent investigators allowing treatment of a total of approximately 125 pediatric epilepsy patients with Epidiolex. The majority of these patients suffered Dravet and Lennox-Gastaut syndromes, but the list of children also comprises a range of other pediatric epilepsy syndromes. The first patients at two sites in New York and San Francisco began receiving treatment during the week before last. INDs each of these sites allow for the treatment of 25 children per site. We understand from the two physicians that approximately 12 children are currently taking Epidiolex with the remainder expected to begin treatment over the coming weeks. It is our expectation that all 50 of those children across the two sites will have become treatment by the end of March, through an ongoing sequence of regular enrollment through February and through March. Approximately three quarters of these initial 50 patients have Dravet syndrome or Lennox-Gastaut. An additional physician site is expected to commence treatment of its 25 patients around the end of March and the remaining 50 patients to other sites are expected to commence treatment around mid-year after receipt of the necessary site licenses from the drug enforcement administration. Since the beginning of 2014, a number of additional U.S. physicians have submitted similar expanded access INDs to the FDA. Under this expanded access IND program, the physicians will collect regular treatment data on seizure frequency, Epidiolex dosing, the use of concomitant antiepileptic medication, adverse events, and other relevant clinical measures. We expect that meaningful data on an initial cohort of patients should be available around the middle of the year with additional data on these patients as well as on the remaining IND patients to follow during the second half of this year. We expect these INDs will generate important safety and tolerability information as well as initial clinical evidence to support the use of Epidiolex across a number of distinct treatment resistant pediatric epilepsy syndromes. Turning now to our formal regulatory development strategy. GW intends to develop Epidiolex for the treatment of both Dravet and Lennox-Gastaut syndrome. Working with some of the leading pediatric epilepsy specialist in the United States, GW has proposed an investigational plan to the FDA for Epidiolex in Dravet syndrome and we expect to hold a pre-IND meeting in the near future. Following this meeting, we intend to submit an IND to the FDA in the first half of 2014 and then to commence an initial clinical trial in the second half of this year. We’ve proposed this initial trial via two-part randomized double-blind placebo-controlled trial of single and multiple doses of Epidiolex to treat Dravet syndrome in children who are being treated unsatisfactorily with other anti-epileptic drugs. Part one comprises the pharmacokinetic and dose finding elements of the trial. Part two is a placebo-controlled extension which will compare the effect of Epidiolex with that of placebo. GW plans to use the results of this initial study to inform discussions with the FDA regarding the designs of additional efficacy and safety trials that could serve as the basis for future NDAs for Epidiolex in both Dravet and Lennox-Gastaut syndromes. Our intention is to commence pivotal trials in 2015. Our objective working with FDA is to establish Epidiolex as the leading cannabinoid based medicine for the treatment of childhood epilepsy disorders through sound, credible and reliable scientific evidence. I note that that while we would like to see the shortest path to approval for Epidiolex, you should assume that GW will be required to go through the normal development and regulatory path with FDA. Needless to say, we will seek every opportunity to minimize the timelines required to submit the initial orphan NDA and would also hope to be in a position to apply for breakthrough status during the course of the development program. Moving on now from Epidiolex. GW has a second product candidate, GWP42006 which features CBDV cannabidivarin, as the primary cannabinoid. CBDV is structurally related to CBD and has also shown anticonvulsant effects across a range of invitro and invivo models of epilepsy. I would particularly like to draw your attention to a very recent publication showing that CBDV suppresses epilepsy associated gene expression in association with significant anticonvulsant effect providing potential for the development of important genetic biomarkers for efficacy in epilepsy. Very exciting findings indeed. We’ve recently completed dosing in a Phase 1 dose escalation single and multiple dose pharmacokinetics and tolerability clinical trial for CBDV. Results are now in data management, and we expect to issue a release with more information about this study in the first half of 2014. From what we already know, I can say that the safety profile of CBDV looks wholly reassuring as there were no serious or severe adverse events during the Phase 1 trial, nor any withdrawal from the trial due to adverse events. Our current expectation is that we will be advancing plans during the second half of 2014 for CBDV to commence a Phase 2 proof of concept trial. While our epilepsy program remains at the forefront of our pipeline activity, it is important to remember that GW is approaching some key milestones for Sativex and also has several other exciting pipeline programs in progress, each of which is supported by promising pharmacology. For Sativex, as Justin mentioned earlier, we expect initial top-line Phase 3 cancer pain data towards the end of this year and we also expect to commence a U.S. targeted Phase 3 multiple sclerosis spasticity trial in the second half. With respect to our earlier stage pipeline, the key areas for activity are as follows. Firstly, we’re close to completing a Phase 2A trial in the treatment of ulcerative colitis for the botanical drug product GWP42003 which features CBD as its primary cannabinoid. Data from this trial is expected around mid-year. Second, we expect to commence a Phase 2B dose ranging trial in the first half of 2014, in the treatment of type-2 diabetes for GWP42004 which features THCV as the primary cannabinoid. Third, we expect to commence a Phase 2A trial in the first half of 2014 in the treatment of schizophrenia using GWP42003. And fourthly, we recently commenced a Phase 1B/2A trial in the treatment of recurrent glioblastoma multiforme, an orphan disease, for a product candidate which combines GWP42002 with GWP42003. In summary therefore, we have a very busy program of R&D activities at present and expect progress across all major areas of the pipeline during 2014. Let me now turn the call over to Adam for the financial review. Adam? Adam George Thank you, Stephen. I intend to provide some general comments on today’s Q1 financial results. A more detailed discussion of our results is given in the press release that we issued earlier today. GW presents its financial results in accordance with International Financial Reporting Standards or IFRS accounting rules, in British pounds sterling, for convenience purposes U.S. dollar equivalence to certain key numbers. Today we’re reporting on the three months ended 31, December 2013. I’ll start with revenues. Total revenues for the quarter were £7.5 million or $12.4 million compared to £5.2 million in Q1 2013, a revenue increase of £2.3 million. This increase is due to two factors. A £1.7 million increase in research and development fees increased to £6.4 million or $10.5 million reflecting progress with the recruitment of patients into the Otsuka-funded Phase 3 cancer pain trials as well as the cost of setting up the MS Phase 3 trial that we expect to start later this year. Sativex revenue of £0.8 million or $1.3 million increased from £0.2 million in the prior period. This reflects the fact that the prior period was impacted by £0.7 million provision for rebate due to Almirall following the adverse pricing decision in Germany in early 2013. In market sales volumes via partners, Sativex increased by 36% over the prior period. This reflects continued growth in Germany plus a strong start in Italy which launched recently. Next, R&D spend, total R&D expenditures for the quarter increased by 43% to £9.2 million or $15.2 million from £6.4 million in the three months until December 31, 2012. This is made up of two elements, the first being the Otsuka-funded Phase 3 R&D-spend that I referred to earlier, which increased to £6.4 million or $10.5 million. Otsuka continue to fund approximately 70% GW’s total R&D spend, but we’d expect this proportion to reduce in the future as we invest more of R&D funds into our pipeline programs. In this quarter, GW funded-spend increased £2.8 million or $4.6 million, the increase is linked to the completion of the CBDV Phase 1 study, they completed dosing recently plus the start-up cost of the glioblastoma study that started in the last quarter. Management and administration spend of £1.5 million or $2.5 million was £0.7 million higher than the prior period. £0.5 million of this increase reflects growth in the provision that we hold for future payroll taxes payable by GW on future stock share auction gains driven by the significant increase in our share price during the period with the remaining increase in costs being cost associated with our NASDAQ listing. This all resulted in a loss before tax for the three months of £3.5 million or $5.8 million which compares to a loss of £2.4 million for Q1 2013. Turning to tax, the £0.7 million or $1.2 million tax credit recorded in this quarter reflects the research and development tax credit that we will claim from the U.K. Tax Authority by the end of the 2014 financial year in respect of R&D spend incurred in this quarter. In the prior period of 31 December 2012, we recorded a £4.4 million tax credit which included a number of one-off items resulting from agreements reached with the U.K. Tax Authority in the first quarter of 2013, these items have not been repeated in this quarter. The net operating cash outflow for the quarter was £2.8 million or $4.6 million compared to £1.7 million outflow in the period ended December 31, 2012. As I’ve already noted, most of this increase is linked to GW funded pipeline research and development spend. We ended the period with cash of £35.2 million or $58.4 million at December 31. Subsequently following the successful completion of our follow-on offering in January, this has been further enhanced by the net proceeds received $94 million giving current cash position approaching £91 million or $150 million. Finally, let me update our 2014 guidance. As I guided in November, we expect continued in-market sales volume growth by our partners to lead to growth for Sativex revenues in 2014. And in terms of milestone income, we continue to expect to receive a $5 million milestone from Otsuka on commencement of the MS Phase 3 study later this year. In terms of R&D spend, I previously guided you to expect GW funded R&D to increase by 40% to 50% this year as we progress a number of clinical stage pipeline programs. Having completed our recent fundraising as per the guidance given in the fundraising prospectus, I now expect this to increase further as the results of planned Epidiolex program spend. In cash flow terms I expect to spend $10 million at the offering proceeds in this financial year. Therefore operating cash outflows plus planned capital expenditure should now result in a cash outflow of approximately $34 million or £21 million for the 2014 financial year. In terms of profitability, we continue to expect to report a loss for the 2014 financial year. The size of that projected loss can be expected to increase in-line with the additional cash spend that I just outlined. Thank you. I would now hand the call back to Justin. Justin Gover Thank you, Adam. GW has had an extremely busy first quarter and look forward to an exciting year ahead during which we expect to update investors on a series of important milestones. With respect to epilepsy we continue to progress, expanded access treatment IND programs throughout the year with initial data being released from mid-’14 onwards. For Sativex, we expect initial top-line Phase 3 data in cancer pain around the end of the year as well as the start of our U.S. MS Spasticity Phase 3 trial in the second half. We also have numerous clinical trials expected across the pipeline with the next Phase 2 data coming from our ulcerative colitis trial. Our model in the past has been to develop cannabinoid-based therapeutics and partner them out as we did with Sativex. However, much has changed over the recent months and we are very excited about the opportunity to retain the full commercial rights to our orphan epilepsy program and leverage that opportunity to the benefit of our shareholders. Finally, as demonstrated by our 15 years of experience dedicated towards cannabinoid therapeutics and our development and regulatory track record established over this extended period, GW is proud to be at the forefront of cannabinoid science. And we believe that we are the company best positioned to lead the way into the future of the therapeutic class. Thank you again for joining us today. And I’m now able to open the line for questions. I’ll turn back to the operator. Thank you very much. Question-and-Answer Session Operator (Operator Instructions). Our first question comes from the line of Ritu Baral with Canaccord Genuity. Please proceed with your question. Ritu Baral - Canaccord Genuity Good morning. Thanks for taking the question guys. I wanted to ask you about some of the details on the investigator studies for Epidiolex being conducted right now. Specifically, you said that they would – the investigators would be capturing dosing data. What are the parameters for dosing in this trial and dose escalation, what are they allowed to do? And what are you – what sort of escalation are you thinking about for the trial that you guys will start in the second half? Stephen Wright Hi Ritu, Stephen Wright here. The dosing recommendations within the investigator led expanded access INDs are all ones which have been agreed with FDA they start at a dose of 2.5 milligrams per kilogram and dose-titrate up to a maximum of 25 milligrams per kilogram, there is a very slight variability between individual INDs. But essentially that’s the top dose that FDA have so far approved within that setting. We’re aiming within our own GW sponsored INDs to explore the same dose range and to one dose range higher than 25 milligrams per kilogram up to 50 mgs per kg. That of course remains a subject for discussion with FDA but that’s our target. Ritu Baral - Canaccord Genuity And do you expect a large degree of variability on the appropriate dose for the patient population? I guess the question is do you expect that certain kids will need a wildly different dose than others? Stephen Wright I mean, I think actually it’s the case with almost every other anti-epileptic drug. There is going to be a range of effective doses that I’m sure that’s correct. And you can probably predict that and the fact that CBD Epidiolex has a relatively low oral bio-availability which almost always means there is going to be variability between subjects in the way they respond to it. Fortunately because we have such a good safety profile, I don’t think that’s of any negative consequence. And actually Epileptologists are very comfortable and very used to the idea that they need to explore dose range in children with epilepsy. Ritu Baral - Canaccord Genuity I see. And the other epilepsy trial – the phase 1 in 42006, what sort of data will we have when you release the phase 1 data, will we have any sort of markers of efficacy? Stephen Wright That study is actually a healthy volunteer. It’s conventional Phase 1 study. So, we do not have any pharmacodynamic markers other than safety. So, what it is, it’s a conventional single dose, single rising dose and then multiple dose pharmacokinetic study. So, we will learn the pharmacokinetics all the normal parameters you would expect, half-life, maximum plasma concentration, time to maximum plasma concentration and so on, both in single dosing and in multiple dosing. And we will be able to link any safety concerns that we might have from the study with the exposure of the volunteers to the drug. So that will then allow us to target an appropriate dose range to move into our proof-of-concept study later this year. Ritu Baral - Canaccord Genuity Got it. And last follow-up and I’ll get in the queue, what differences do you predict in the clinical profile between CBD and CBDV, depending on the work that you’ve done? Justin Gover I think it’s almost certain that we will not be targeting the same types of epilepsy straight off the bat with 42006 CBDV as we are with CBD. So the proof-on-concept with CBDV will be a more conventional approach in complex partial seizures and we will then determine exactly which patient population to go into in pivotal studies with CBDV. So, we don’t at this point have any expectation of a markedly different profile for the one than for the other. But we will almost certainly be exploring different epilepsy subtypes with CBDV than with CBD. Ritu Baral - Canaccord Genuity Great. Thanks for taking the question guys. I appreciate it. Operator Thank you. Our next question comes from the line of Josh Schimmer with Piper Jaffray. Please proceed with your question. Josh Schimmer - Piper Jaffray Hi, thanks for taking the questions. First of all, any sense on the size of the Epidiolex placebo-controlled phase of the Phase 2 study? And when would you expect the randomized portion of that trial to begin? And then last, what’s giving you the confidence now to advance so quickly into a placebo-controlled study, has there been any change in your observations or any new findings that’s driven that? Stephen Wright Thanks Josh, Stephen Wright here again. Very broadly we’re anticipating that there would be 60 patients in each of the two pivotal studies that we’re proposing. And that sample size is based on an assumption of around about 55% responder rate on drug and about 25% responder rate on placebo. Those numbers work in that kind of setting. Of course, we’re yet to determine whether the expectations of FDA for a suitable database size will be met by those proposals and we’ll find that out quite soon. But that’s the way we framed our approach. Do we think, it’s too soon to be going into placebo-controlled trials? The answer is no, we don’t. The pivotal portions of those studies wouldn’t start until the end of this year or the beginning of next year actually more likely. And by that time we will have quite a significant amount of guidance from the expanded access IND open-label data that we’ve seen up to that date. I should point how that the studies that we’ve proposed in start what we called part A, which is a dose ranging pharmacokinetic and safety evaluation. And that part is also placebo-controlled. So, actually the entire body of GW-sponsored clinical trial work under an IND will be placebo-controlled. Josh Schimmer - Piper Jaffray So, and you said two pivotal studies, is that two in Dravet or one in Dravet and one in Lennox-Gastaut? Stephen Wright The current proposal is that we will propose two in Dravet. Clearly, if at some stage, due to accumulation of data FDA became comfortable with a single pivotal study if it was sufficiently compelling or enough, then that would be great. I think it would be injudicious of us to propose that off-straight off the bat right now. Josh Schimmer - Piper Jaffray Got it. And maybe a last question. Can you give us a sense of process or timing in listing what seems to be a pretty absurd scheduling of Epidiolex as a Schedule 1 drug? Who makes the decision to change than scheduling? What has to happen before that? And is there any action or activities from parents, families, or physicians to facilitate that or there is there anything that could be doing? Justin Gover Josh, hi, it’s Justin here. I’ll reflect off Stephen on that one. I mean, it’s obviously a major topic of discussion the whole issue is of course as you well know. I mean, at the end of the day there is a systematic approach to rescheduling. And again just as you’re hearing with respect to our development program. I think for now I think you just have to assume that the scheduling will change on approval of an FDA-approved prescription medicine. I don’t think we can comment beyond that. Obviously we’re well aware that there is a lot of activity. And I’m sure there is discussion within the medical community and other parts of bodies within the U.S. about this. But from our perspective it’s a schedule 1 substance all the sites that we use in the treatment of INDs have Schedule 1 licenses. And in that respect, actually although it is, and you might say maybe absurd but actually the process to work, we are able to go through this licensing process. As you know, children are starting to be started and sponsored studies will be done. As they are with Sativex, Sativex is still Schedule 1 and we were able to navigate through that. So, I don’t think it will harm our own progress. Josh Schimmer - Piper Jaffray Got it. Thanks very much. Operator Thank you. Our next question comes from the line of Joseph Schwartz with Leerink Partners. Please proceed with your question. Joseph Schwartz - Leerink Partners Hi, thanks very much. I was wondering if you could tell us how focused are you on keeping European development at a pace that mirrors the United States and what kind of activities are ongoing outside the US, such as with the EMA? Stephen Wright Joseph, hi, it’s Stephen Wright here. Yes, we are indeed going to be recruiting both within Europe and the United States in our pivotal clinical trials. And we are having preliminary discussions with the EMA during March. Joseph Schwartz - Leerink Partners Okay. And then how are you thinking of going after orphan epilepsies outside the US and EU? Is there any orphan drug exclusivity route in places like Latin America that you can take advantage of? Stephen Wright At this point, our ambitions extend to the EU and to United States. I think you’ve raised a very good point. And clearly, in due course, we need to explore how rapidly we can globalize the opportunity as yet we haven’t fully done that. Joseph Schwartz - Leerink Partners Okay. And then lastly, regarding the GWP42003 and ulcerative colitis, I think that’s a 10-week dose escalation study, and you said you were close to finishing the dosing with data mid-year. I was wondering how did you settle on the 10-week duration and what is the up-titration schedule, was that informed by any of the anecdotal observational studies with CBD-enriched cannabis? How likely do you think it is that patients will be able to get to a meaningful therapeutic dose in that time frame, how have you designed that? Stephen Wright Sure. I mean, firstly the 10-week dosing period. The objective of the study is to induce remission in patients actually who fail to have remission induced by first line of therapy. And in general, I think everyone would accept if you don’t induce remission over 10-week period, that’s a treatment failure. Clearly, if we were looking at the maintenance of remission, we would want much longer exposures. But for the induction of remission, most of this is actually 6-8 weeks. So, I think we’re very comfortable with the 10-week period. In terms of the dose-titration this – the material being used in the ulcerative colitis study for very good pharmacologic reasons contains a small proportion of THC. And it’s actually the THC within the material, THC has desirable properties on gastrointestinal ability. It’s because the presence of the THC that we’re dose-titrating upwards. You’ll appreciate from our experience with Sativex and a lot of Phase 1 experience with CBDX track that we’ve become very familiar with the rate at which dose increases can occur. So, I think we’re very comfortable that we’ve achieved a certain we’re able to achieve both the rapid and appropriate dose titration. I hope that answers your questions. Joseph Schwartz - Leerink Partners Yes, that’s really helpful. Thanks. Operator Thank you. Our next question comes from the line of Phil Nadeau with Cowen & Company. Please proceed with your question. Phil Nadeau - Cowen & Company Hi, thanks for taking my questions. First just a housekeeping question on the 2014 guidance. If I interpreted your comments correctly, it sounds like you’re guiding to a 40% to 50% increase in R&D plus $10 million. Is that correct or did I misinterpret what you said? Adam George This is Adam George. Yes, I have said that we are going to spend $10 million. I wasn’t specific that all of that will be going through the R&D line but the majority of it will be. So, yes, your interpretation is there or there about. Phil Nadeau - Cowen & Company Okay, great. My second question is on the trial design that you discussed for the pivotal trials. I think you said a 55% responder rate on drug, 25% on placebo. I was curious about the placebo response rate. I had thought Dravet was very refractory epilepsy. How would placebo be causing a 25% response rate? How would you be defining response to see that level of response from placebo? Justin Gover The definition of a responder rate is better than 50% reduction in seizure frequency. And I completely agree with you that in general Dravet is thought to be very treatment resistant. However, if you look at occasional published studies for example, with stiripentol in Dravet, there is a distinct placebo response. And our U.S. Chief Investigator Dr. Oren Dubinsky has published some very elegant papers on placebo responses in patients with epilepsy, which I think mean that it would be injudicious of us to predict a very, very low placebo response in the setting of a Phase 3 clinical trial. I think we need to do that and were there then a placebo response of some significance to occur we would be caught with egg in our face and that’s not something we want to be. Phil Nadeau - Cowen & Company I guess the – that’s a very fair point. And I guess the broader question I’m wondering about is – a lot of us are interpreting the data or the press reports about reductions in the seizure frequency from CBD enrichment of medical marijuana. And soon I think we’ll all be interpreting the reduction in seizure frequency we see from the treatment INDs. Should we kind of assume 25% of patients would probably have a reduction in seizure frequency no matter what they got, when we try to interpret these anecdotes or I guess give us some sense of how we should interpret the uncontrolled anecdotes that we see? Justin Gover Yes, no, I don’t think so. And I think the answer is that placebo-controlled clinical trial in a very formal setting with a very fixed primary outcome measure on different animals than what happens in real life and in the clinic. And I hope the two are complimentary when we come to submit our orphan NDA for Epidiolex in Dravet. So, I did mention during the presentation that we are in our view being relatively conservative with our proposals to FDA to the investigational plan. And I think this discussion about the placebo response in clinical trials illustrates exactly that we are being relatively conservative. And we would suggest that that may offer some potential upside if it turns out the placebo response is in fact somewhat lower than that. So, I think that’s how I’d position our – the way we’re powering our clinical trial. Phil Nadeau - Cowen & Company Okay, great, and one last question. You have conducted the survey of patients who have been on CBD-enriched medical marijuana, which has shown a pretty dramatic reduction in seizure frequency for those patients. What I’m actually curious about is just the patient makeup of the survey. If I remember correctly, the vast majority of patients were Dravet with only one or two Lennox-Gastaut patients in the survey. And I’m curious about that. It seems like there’s actually probably more Lennox-Gastaut patients out there than Dravet. So why was the population skewed toward Dravet? Is it something about the age of the kids or the severity of Lennox-Gastaut that means they’re not going on CBD-enriched medical marijuana whereas Dravet is? Stephen Wright You’re making very good point. Can I first look at your first point Nad, because it refers back to my previous answer. If you look at the results found in that published survey, about 64% of the children overall got a better than 50% reduction in seizure rate. That’s more or less what we are aiming at in our clinical trials. So I think that’s a kind of another reference point that we can use. I think 13 out of the 19 children in there were Dravet children. And I think it was tilted towards Dravet children, simply because of the particular interest of the Dravet Foundation actually. And that’s my understanding. And I believe that Dravet Foundation is more active currently than Lennon-Gastaut Foundation. I think that’s probably the simple reason. Phil Nadeau - Cowen & Company Okay, so there’s no reason to think CBD would work less or be less appropriate for a Lennox-Gastaut child than a Dravet child? Stephen Wright No, and there are published case reports out there showing dramatic improvements in Lennox-Gastaut children as well. Phil Nadeau - Cowen & Company Great. Thanks for taking my questions. Operator Thank you. Our next question comes from the line of Samir Devani with WG Partners. Please proceed with your question. Samir Devani - WG Partners Hello everyone. I’ve got a few questions. Just, the first question is for Stephen. Just going back to the seizure dosing for Epidiolex, what sort of adverse events would you expect to see as you approach the NTD? Stephen Wright Honestly minor and non-specific adverse events. We’ve seen zero in the way of target organ toxicity, even at very, very high doses in all toxicology studies. So, we’re talking about things like headache, minor gastrointestinal disturbances that kind of thing Samir. So, nothing I think specific at all. Samir Devani - WG Partners Okay. And just moving on to the non-orphan epilepsy opportunity, what’s the strategy there? Stephen Wright I think the strategy remains to be fully elaborated. Certainly the proof-of-concept with CBDV currently, we’re aiming to target complex partial seizures, probably in adolescence. But even that remains to be fully determined. We believe that that would give us the best, what can I say, that would allow us to reach the fork in the road which gives us the most productive routes then to follow. Samir Devani - WG Partners And then, just finally one bit of housekeeping, in terms of Sativex, I think you had applied for regulatory approval in the Gulf States. I’m just wondering if you can give us an update as to how that’s going. Justin Gover Well, we have regulatory approval in Kuwait that’s done and dusted. And we’re waiting for more regulatory approval in the other Gulf member states. We have had our manufacturing plant satisfactorily inspected by the Gulf coordinating committee. So all the, kind of pieces are in place. Samir Devani - WG Partners Okay. Were we not expecting some milestones from approval in Gulf States or is that no longer the case? Justin Gover There, hi Sameer, it’s Justin here. There is milestone associated with a combination of a couple of Gulf States. But it’s a relatively immaterial milestone. And but, yes, and I mean, the approvals are still expected. Samir Devani - WG Partners Great. Thanks very much. Justin Gover Okay. Operator Thank you. Our next question comes from the line of Bert Hazlett with ROTH Capital. Please proceed with your question. Bert Hazlett - ROTH Capital Partners Thanks. I just have a brief one. Could you remind us of the intellectual property strategy for Epidiolex? Clearly you have orphan drug designation for Dravet. Are there additional strategies in place beyond orphan drug for the individual settings, and if so, could you comment on those? Thanks. Justin Gover Yes, hi, Bert. Thanks. This is Justin here. So, there are a couple of specific use related patents for CBD in the epilepsy therapeutic area, which are going through prosecution right now as well as some IP that relates to the purification and other sort of process steps that are involved in the production of the product. So, there is literature around CBD and epilepsy. So those patents are relatively focused. I think, and it is undoubtedly the case that one of our ambitions is to – is also within the concept of an epilepsy portfolio to be looking not just at Epidiolex and the protections that are provided both by exclusivity in this IP but also thinking more broadly relevant to the previous question actually about the role of CBDV as we move forward which is also well protected. So, I think there is a matrix approach that we’ve taken here which is not the similar to Sativex actually, the Sativex doesn’t have a single key patent, there are various patents around this. But I think it’s probably fair to say that the orphan exclusivity is particularly important for CBD. Bert Hazlett - ROTH Capital Partners And just one follow-up. You have the patents under prosecution. Could you, it’s always a mystery as to how that progresses. Could you comment on the general status? Do you think you’re close to notice allowance or are they in early days in terms of being prosecuted? Justin Gover Our approach for the IP prosecution is over the last 15 years has been attended to use the U.K. Patent Authority as a kind of initial text if you will. And those patents we can get opinions quite quickly and prosecute quite quickly. So, we do have opinions. And so I think you can take it from that the prosecution in the U.S. is continuing on the basis of feedback that we’ve received already from the U.K. examiners. Bert Hazlett - ROTH Capital Partners Okay. Operator Thank you. Ladies and gentlemen, we’ve come to the end of our allowed time for questions. I would like to now turn the floor back over to management for any closing comments. Justin Gover All right, thank you. So, it’s Justin Gover here, just wrapping up. Thank you for all your attention this morning. I hope we’ve been able to clarify some key aspects of the news flow for this year in particular with regards to the evolution of the epilepsy program through the remainder of 2014. And we look forward to updating you in with our second quarter results in a few months’ time. Many thanks. Operator Thank you. This concludes today’s teleconference. You may disconnect your lines. Thank you for your participation.

Dear Stoner: Can THC-V help with weight loss? By William Breathes Thursday, Feb 6 2014 http://www.westword.com/2014-02-06/news/thc-v-and-weight-loss/ Dear Stoner: Is there any truth to the Internet rumor that some strains that contain high levels of THC-V can actually help with weight loss by reducing appetite? If so, do you know of anyone who needs a subject for a long-term scientific study? Big J Dear Big J: We've done some digging, and, yes, there is some truth to the tetrahydrocannabivarin (THC-V) claims. But we don't think that bong rips will be replacing exercise on The Biggest Loser any time soon. About ten years ago, scientists at Aberdeen University in Scotland realized that THC-V caused the opposite reaction of THC in the human body: It doesn't get you stoned, and it blocks the appetite surge caused by THC. It was so good at the latter, actually, that GW Pharmaceuticals announced in 2007 that it was starting research on the compound as a potential treatment for obesity and obesity-related disorders like diabetes. Sounds promising, right? But the problem is that strains high in THC-V aren't as easy to come by as they should be, having been inadvertently weeded out of the gene pool. Certain levels of THC-V also kill the buzz you get from THC by blocking the THC receptors in your body. Since most cannabis breeders have been looking for ways to increase the potency of their plants over the past three or four decades, they probably weren't keeping plants high in THC-V. Now that we've got more dedicated medical cannabis breeders, though, I can see this becoming yet another cannabinoid like CBD that people will seek out specifically. But it's going to take some time to identify strains that regularly test high for THC-V, much like it has taken time to find high-CBD strains. Anecdotally, hazes and African-sourced strains like Durban Poison tend to be higher in THC-V than others. Subcool Genetics also claims to regularly get high THC-V percentages from its Jack the Ripper strain. So while there may be a pot-derived weight-loss drug or specific "skinny strains" down the line, currently our best advice on how to use marijuana to lose weight is to get stoned, go to the gym, and zone out on your iPod while ripping through reps on the Stairmaster. Dear Stoner: I just needed to know if I can purchase from y'all without a red card. Les (via the potline) Dear Les: Despite the plethora of advertisements for dispensaries in the back of our paper, we don't actually sell weed — red card or not. For searchable listings of all recreational shops currently open in Denver, click over to the MJ page at westword.com.

06 de Fevereiro de 2014• 16h41 Johnny Depp leva cachimbo de maconha a passeio com Marilyn Manson http://diversao.terra.com.br/gente/johnny-depp-leva-cachimbo-de-maconha-a-passeio-com-marilyn-manson,62eb6f08d7804410VgnVCM20000099cceb0aRCRD.html Astro de 'Piratas do Caribe' ao lado do cantor de metal industrial, clicados em Los Angeles Foto: TMZ / Reprodução Os paparazzi definitivamente não deixam nenhuma celebridade em paz na cidade de Los Angeles, onde boa parte delas está concentrada na costa oeste dos EUA. E conseguiram fotografar um passeio de Johnny Depp e Marily Manson, em imagem publicada pelo site TMZ, nesta quinta-feira (6). Os dois foram clicados caminhando enquanto o ator de 50 anos segurava na mão direita um pequeno cachimbo de vidro, usado para fumar maconha, e um isqueiro vermelho. A amizade já vem de longa data: o ator, também músico amador, inclusive já gravou, um cover para a canção You´re So Vain junto com o cantor

06-02-14 17:44 Uruguai estuda limitação da venda de maconha a 10 gramas semanais http://portuguese.ruvr.ru/news/2014_02_06/Uruguai-estuda-limitacao-da-venda-de-maconha-para-10-gramas-semanais-2649/ Foto: Flickr.com/Paciarotta/cc-by-nc-sa 3.0 O governo do Uruguai está estudando a possibilidade de limitar a venda de maconha a apenas 10 gramas por semana e por pessoa, numa tentativa de aperfeiçoar a nova lei da maconha e regular o acesso às suas sementes. A proposta dos assessores do presidente uruguaio José “Pepe” Mujica deverá fazer parte da regulamentação da lei da maconha. Com a aplicação da mesma será garantida a comercialização de 40 gramas mensais por pessoa. Caso a proposta seja aprovada pelo Senado uruguaio na sua primeira discussão, o presidente Mujica deverá aprovar o decreto regulamentar da lei em abril de 2014.